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NEUTRALIZING SERUM ACTIVITY 
 
Johannes F. Scheid, Ph.D. 
The Rockefeller University 2014 
 
 
Antibodies to conserved epitopes on the HIV surface protein gp140 can protect against 
infection in non-human primates, suggesting that vaccines that elicit such antibodies 
would be protective. Some HIV infected individuals develop high titers of broadly 
neutralizing IgG antibodies in their serum, but until recently very little was known about 
the specificity and activity of these antibodies.  To characterize the broadly neutralizing 
memory antibody responses to HIV we cloned 1078 antibodies from HIV envelope 
binding memory B cells from eight HIV infected patients with broadly neutralizing 
antibodies.  We found that in these patients, the B cell memory response to gp140 is 
composed of up to 50 independent clones expressing high affinity antibodies to the gp120 
variable loops, the CD4 binding site, the co-receptor binding site, to a new neutralizing 
epitope that is in the same region of gp120 as the CD4 binding site and to gp41. In four 
patients highly potent broadly neutralizing antibody clones directed to the CD4 binding 
site were isolated. Despite extensive hypermutation, these broadly neutralizing CD4bs 
antibodies shared a consensus sequence of 68 IgH chain amino acids and arose 
independently from two related IgH genes. Thus, the IgG memory B cell compartment in 
the selected group of patients with broad serum activity to HIV is comprised of multiple 
   
clonal responses. Neutralizing activity is directed against several epitopes on gp120 with 
some closely related CD4 binding site directed antibody clones showing highly potent 
neutralizing activity.   
For the first time, this study has attempted to systematically describe on a monoclonal 
level the composition of broadly neutralizing serum activity against HIV.  
The techniques and antibodies presented in this work are transforming our understanding 
of possible targets and routes for HIV vaccine strategies and provide powerful tools for 
possible HIV treatment approaches. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
"What we want to do is remain innovative 
and always keep our eyes on the disease." 
Ralph Steinman 
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Chapter 1 
Introduction 
 
The HIV Vaccine Problem 
Since its discovery in 1981, HIV has killed over 25 million people and currently more 
than 33 million humans are infected worldwide. Despite extensive research efforts over 
the last three decades, a vaccine against HIV remains elusive(Karlsson Hedestam et al., 
2008; McElrath and Haynes, 2010; Moir et al., 2011; Walker and Burton, 2008). This 
introduction will portray some of the main challenges in HIV vaccine design and discuss 
the role of neutralizing antibodies in addressing them. 
HIV Envelope 
In order to allow infection, the HIV envelope protein (env) needs to interact with surface 
receptors on the target cell. This makes env the main target of an HIV vaccine. Early 
approaches using soluble envelope protein or inactivated virus as immunogens have not 
met with the same success as for other pathogens, such as influenza. This failure roots in 
HIV envelope diversity and other structural traits that still are not entirely understood. 
Diversity 
HIV displays a large diversity of envelope versions within each patient and in the 
population(Keele et al., 2008; Salazar-Gonzalez et al., 2009; Taylor and Hammer, 2008; 
Wei et al., 2003). Like other retroviruses, HIV depends on a reverse transcriptase to 
amplify its genome. The HIV reverse transcriptase exhibits an exceedingly high error 
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rate(Keulen et al., 1997; Roberts et al., 1988). In addition, sub-lethal levels of the human 
anti-viral protein APOBEC3G might further enhance HIV diversity by introducing A-G 
mutations(Keele et al., 2008; Rose and Korber, 2000; Wood et al., 2009).  
Envelope Structure 
Limited structural understanding of the native HIV envelope protein poses another 
impediment on HIV vaccine design. So far, crystal structures are only available for 
artificially stabilized forms of the envelope subunits(Cardoso et al., 2005; Chan et al., 
1997; Chen et al., 2005; Diskin et al., 2010; Kwon et al., 2012; Kwong et al., 1998; 
Pancera et al., 2010; Shi et al., 2010; Weissenhorn et al., 1997). The main limitations for 
crystallization of the entire HIV envelope protein are both extensive glycosylation and 
structural flexibility.  
However, cryo-electron microscopy images have shed some light upon the assembly of 
functional envelope spikes on HIV particles(Liu et al., 2008; Mao et al., 2012; Zhu et al., 
2006). Although limited in resolution, the images show the envelope spike as a trimer of 
gp120-gp41 heterodimers. The three gp41 monomers provide the transmembrane domain 
and form a mushroom shaped structure at the base of the trimer(Liu et al., 2008). The 
three gp120 monomers are placed on top of the gp41 base. In addition, the images 
provide insight into the orientation of the gp120 variable loops 1/2 and 3, which were 
deleted from previous core crystal structures. The loops seem to be oriented toward the 
apex of the trimer with variable loops 1/2 stabilizing the spike using strong inter-
monomeric contacts(Liu et al., 2008). This is in contrast to the arrangement suggested by 
an unliganded simian immunodeficiency virus (SIV) core crystal structure, which placed 
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the V1/2 loops at the base of the trimer(Chen et al., 2005). The reasons for this 
discrepancy are not clear and underscore the necessity for structural characterization of 
diverse HIV strains in different conformational states.  
High levels of diversity and limited understanding of the envelope structure pose 
challenges for HIV vaccine design. But reports of broadly neutralizing serum responses 
suggest that the human immune system is able to target conserved parts of the HIV 
envelope(Doria-Rose, 2010; Gray et al., 2011; Mikell et al., 2011; Sather et al., 2008; 
Simek et al., 2009; Stamatatos et al., 2009; Walker et al., 2010; Weiss et al., 1985; Weiss 
et al., 1986). The perspective of copying such immune responses with a vaccine has 
placed the characterization of broadly neutralizing antibody responses against HIV into 
the centre of HIV vaccine research. 
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HIV Envelope Antibody Response and Escape 
HIV envelope in early infection 
HIV infection most commonly is mediated by a small number of virions. Around 80% of 
heterosexual transmissions are established by a single virus(Abrahams et al., 2009; Keele 
et al., 2008). The rates of multiple-variant transmissions are higher among men who have 
sex with men(Li et al., 2010) and in association with inflammatory genital 
infection(Haaland et al., 2009). Thus, transmission seems to pose a significant bottleneck 
to the virus, which is supported by early signature mutations in the envelope that might 
increase infectivity. One example for such a signature mutation is the loss of a possible 
N-linked glycosylation site (PNLG) at residues 413-415(Derdeyn et al., 2004; 
Gnanakaran et al., 2011). After this bottleneck the viral population rapidly diversifies, 
allowing formation of up to 50 versions of a single given epitope within a few weeks and 
escape from early T cell mediated selective pressure(Wood et al., 2009) (Fischer et al., 
2010) 
HIV envelope antibody response is delayed 
The first detectable serum antibody response to HIV env arises shortly before the peak 
viremia in the third week (reviewed in (Cohen et al., 2011; McMichael et al., 2010)). 
Initially, this response is directed to gp41 and is believed to have little effect on early 
viral dynamics(McMichael et al., 2010; Tomaras et al., 2008). Gp120 antibodies develop 
after the gp41 response and are believed to preferentially target the variable loop 3(Davis 
et al., 2009; Tomaras et al., 2008). In serum neutralization assays, autologous neutralizing 
activity requires at least 4-14 weeks to develop. Heterologous neutralization is 
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significantly delayed and therefore rarely detected within the first year of infection(Gray 
et al., 2007; Liao et al., 2013; Mikell et al., 2011; Richman et al., 2003; Wei et al., 2003).  
Of note, most of these observations were acquired with polyclonal serum neutralization 
tests in conjunction with sequence analysis of patient envelope genes. More recent efforts 
have identified antibody mediated selection pressure earlier than detectable in serum 
neutralization assays by combining single envelope genome analysis with monoclonal 
antibody characterization. In the patients studied, the epitopes targeted in this early 
effective antibody response included the V1/2  and V3 loops and the gp120 outer domain 
as well as the CD4 binding site (CD4bs)(Bar et al., 2012; Liao et al., 2013).  
HIV envelope escapes from antibody pressure 
HIV avoids autologous neutralization through escape mutations. This was first 
demonstrated for HIV in a series of experiments that tested serum neutralizing activity 
against autologous viruses from different time points. Serum was able to neutralize virus 
from previous time points better than contemporaneous virus(Richman et al., 2003; Wei 
et al., 2003). Escape mutations often involve PNLG's (Wei et al., 2003) (Rong et al., 
2009). As each N-linked glycan can reach the size of one entire V3 loop these mutations 
lead to considerable changes on the envelope surface. This observation introduced the 
model of a mobile glycan shield as a means of continuous viral escape (Wei et al., 2003). 
Interestingly, escape is mediated both by loss and gain of glycosylation sites(Gnanakaran 
et al., 2011; van Gils et al., 2011). Escape from neutralizing glycan-antibodies is achieved 
by loss of glycan sites such as N188(Gnanakaran et al., 2011) whereas addition of other 
glycan sites helps to shield targets of neutralizing activity. Other escape mechanisms in 
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chronic HIV infection involve amino acid mutations and additions in the V3 and in V1/2, 
which are believed to mediate neutralization resistance by shielding parts of the envelope 
spike (see below and(Euler et al., 2012; Moore et al., 2009; Rong et al., 2009)).  
Recently, a first study combining monoclonal anti-HIV B cell isolation and viral 
envelope characterization has prospectively followed in one patient the evolution of a 
broadly neutralizing antibody clone and the concomitant viral escapes (Liao et al., 2013). 
In this case the interplay between constant viral escape and strong selection pressure by a 
CD4bs directed antibody clone eventually lead to the development of strong heterologous 
neutralization after more than 70 weeks of infection (Liao et al., 2013).  
In summary, there is ample evidence for a delayed development of an effective antibody 
response in HIV infection. Once mounted, this response exerts selective pressure on the 
virus by following a constantly evading viral population. The recent development of high 
throughput single env genome analysis combined with monoclonal antibody studies 
hopefully will provide a more detailed portrait of this continuous dialogue between 
antibodies and env.  
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Broadly Neutralizing Sera 
Definition and Frequency 
Reports of neutralizing serum activity early in the epidemic (Weiss et al., 1985; Weiss et 
al., 1986) were difficult to interpret because most HIV neutralization assays at that time 
used T cell line adapted HIV strains. These were found to be readily neutralized and do 
not reflect true primary isolates in natural infection(Li et al., 2005). The recent 
development of standardized, tiered neutralization assays (Li et al., 2005) for large-scale 
HIV patient screens has established that 10-30% of patients eventually develop a broadly 
neutralizing antibody response against difficult to neutralize primary isolates(Doria-Rose, 
2010; Gray et al., 2011; Mikell et al., 2011; Sather et al., 2008; Simek et al., 2009; 
Stamatatos et al., 2009; Walker et al., 2010). 1% of patients seem to fall into a more 
stringently defined category of "elite neutralizers". These sera are able to potently 
neutralize more than one strain in four different clade groups of a selected panel of 
isolates(Simek et al., 2009).  
Factors associated with broad neutralization are unknown 
Broad neutralization usually is acquired over several years(Gray et al., 2011; Sather et al., 
2009) and peaks around four years after infection. It is not understood what the clinical 
relevance of broad serum neutralization in patients is, as it does not lead to viral control 
or slower disease progression(Euler et al., 2010; Pereyra et al., 2008).  
Also, it is not clear what causes this activity. Several studies found a correlation between 
the development of broad neutralization and either low CD4 counts or high viral loads or 
both(Doria-Rose et al., 2009; Gray et al., 2011; Sather et al., 2009; van Gils et al., 2009). 
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One of the studies(Gray et al., 2011)only found this correlation if CD4 counts and viral 
loads from set point (6 months into infection) and not from later time points were 
included in the analysis. This correlation implies, that early events in infection might 
influence the later development of broad neutralization. In addition, analysis of envelope 
sequences from 69 patients uncovered signature sequences in env that are associated with 
high or low neutralizing activity in the same patients(Gnanakaran et al., 2010). As 
discussed below, the recruitment of particular germline progenitor B cells into germinal 
center reactions is important for initiating the development of broadly neutralizing serum 
activity. Therefore, the idea that certain viral envelopes might be more efficient in 
engaging the "right" germline progenitors is an intriguing concept. 
In summary, the reasons why some individuals develop broadly neutralizing serum 
activity are not yet clear. However, early CD4 counts and viral loads as well as certain 
viral envelope features might play a role in this evolution.  
Targets of broad Neutralization 
In an attempt to identify the targeted epitopes, broadly neutralizing serum samples have 
been extensively characterized by serum fractionation using mutant forms of the env 
protein. The results of these studies and their implications are reviewed here. 
Serum fractionation studies are limited for several reasons: Firstly, they are unable to 
identify monoclonal antibodies and therefore display a limited resolution. Also, it is 
difficult to evaluate neutralization potency of an antibody fraction in a bulk mixture, in 
which the quantitative representation of single antibody clones is unknown. Nevertheless, 
these studies have provided a first insight into broadly neutralizing epitopes. 
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Gp120 
CD4 binding site 
Paramagnetic-bead-immobilized gp120 depletes significant neutralizing activity in a 
large fraction (around 50%) of broadly neutralizing sera(Binley et al., 2008; Tomaras et 
al., 2011; Walker et al., 2010). Some of this activity is directed to the CD4 binding site 
(CD4bs), the site of interaction between env and its main receptor on the target cell.  
Since the discovery of CD4 as the main receptor for HIV infection (Dalgleish et al., 
1984; Sattentau et al., 1986)the CD4bs on gp120 has received widespread 
attention(Weiss et al., 1988). In particular the observation that soluble CD4 neutralizes 
HIV broadly(Smith et al., 1987), has raised the question if antibodies might structurally 
mimic this interaction.  
The first gp120 core crystal structure was obtained in complex with CD4 and an antibody 
to the CD4 induced site (see below)(Kwong et al., 1998). This landmark study has helped 
define the CD4bs on gp120. CD4 contacts the inner domain, outer domain and bridging 
sheet of gp120. This contact site forms two cavities on gp120 that accommodate residues 
with sequence variability. They are surrounded by highly conserved residues such as 
Asp368, Glu370, Trp427 and Asp457(Kwong et al., 1998). Two of these residues, Asp368 and 
Glu370 at the Phe43(CD4) cavity are also important contact sites of the neutralizing CD4bs 
antibody b12(Burton et al., 1991; Wyatt et al., 1998), which confirmed that neutralizing 
antibodies can target structurally conserved parts of the CD4bs (Binley et al., 2004; 
Wyatt et al., 1998).  
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A point mutant in one of these conserved sites, gp120D368R, was used in serum 
fractionation studies(Binley et al., 2008; Li et al., 2007; Tomaras et al., 2011; Walker et 
al., 2010). In some sera with gp120 directed broad neutralization, adsorption with the 
mutant left neutralization unaltered. In these cases, neutralization could be mapped to the 
CD4bs. Intriguingly, some of these fractions displayed potent neutralizing activity against 
b12 resistant viruses (see below)(Li et al., 2007), suggesting that monoclonal CD4bs 
antibodies superior to b12 might exist (see below). 
CD4 induced site 
The CD4 induced site (CD4i) is an epitope on gp120 that is exposed after binding of 
gp120 to CD4(Sattentau et al., 1993; Thali et al., 1993) and overlaps with the coreceptor 
binding site of gp120(Rizzuto et al., 1998; Wu et al., 1996). The epitope involves the 
β20–β21 ribbon of the outer domain and stems of variable loops 1/2 which upon CD4 
binding together form the bridging sheet(Chen et al., 2005). The epitope's conservation 
among different viral strains makes it an attractive target for broad neutralization(Kwong 
et al., 1998; Rizzuto et al., 1998). On the other hand, the epitope is concealed by variable 
loops V1/V2 and V3(Kwong et al., 1998) and is assembled properly only after CD4 
binding(Chen et al., 2005). This might explain why the best antibody of this group, 17b, 
shows only limited neutralization breadth and potency against primary isolates(Seaman et 
al., 2010).  
The role of CD4i antibodies in broad serum neutralization could not be clearly defined by 
serum fractionation. Some studies did not find significant activity to this epitope(Binley 
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et al., 2008; Tomaras et al., 2011). Another study did reveal some broad CD4i activity (Li 
et al., 2009)using a point mutant of the key residue, gp120I420R.  
In summary, the CD4i is a conserved but well concealed epitope on gp120. Serum 
fractionation might not be an appropriate tool to characterize the role of CD4i antibodies 
in broad neutralization. The recent identification of CD4bs directed antibodies that are 
sensitive to the CD4i point mutation gp120I420R (see below) renders this reagent 
insufficient to clearly differentiate between CD4bs and CD4i directed activity. However, 
CD4i antibodies in serum do neutralize broadly in the presence of CD4(Decker et al., 
2005) and are believed to maintain CD4 dependence of HIV during infection(Kolchinsky 
et al., 2001). 
Variable Loop V3 
To directly evaluate the role of antibodies directed to variable loops V1/2 and V3, sera 
with gp120 directed broad neutralization were fractionated with a gp120 core that lacks 
these variable loops(Dhillon et al., 2007; Tomaras et al., 2011). The inability to adsorb 
gp120 directed neutralization with gp120 core in some cases suggests that a significant 
fraction of broad neutralization in those patients is directed to the variable loops (Dhillon 
et al., 2007; Tomaras et al., 2011). 
Next to the CD4i, the V3 loop is the second site of interaction with the coreceptor on the 
target cell.  Therefore it is required for viral infectivity(Cao et al., 1997) and determines 
CXCR4 or CCR5 tropism(Hwang et al., 1991). 31-39 amino acids long, the loop is 
divided into a base, a flexible stem and a β-hairpin tip(Huang et al., 2005). In the 
unliganded state the V3 is located laterally on the trimer apex(Liu et al., 2008). It might 
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contribute to inter-monomeric interactions(Liu et al., 2008) and to neutralization 
sensitivity of the envelope spike. Upon binding to CD4 the loop is released from this 
position and points directly towards the target cell(Liu et al., 2008). This exposed 
position allows both the base and the tip of the loop to interact with the coreceptor as a 
"molecular hook"(Huang et al., 2005).  
The role of V3 directed antibodies in vaccine design and broad neutralization has been 
heavily debated. During acute infection, V3 specific antibodies are among the first to 
show autologous neutralizing activity (Davis et al., 2009; Goudsmit et al., 1988). This 
observation early on in the HIV epidemic has lead to the term "principal neutralizing 
domain" and has inspired several vaccination approaches(Goudsmit et al., 1988; 
Javaherian et al., 1990; Javaherian et al., 1989; Zolla-Pazner et al., 2009). However, 
restricted neutralizing breadth and potency of V3 directed monoclonal antibodies(Binley 
et al., 2004; Gorny et al., 2004) has raised the concern, that although immunogenic, the 
V3 loop might be not accessible to antibodies on difficult to neutralize primary 
isolates(Hartley et al., 2005; Wu et al., 2008).  
In order to assess the contribution of this class of antibodies to broadly neutralizing serum 
activity, serum studies used V3 loop peptides as inhibitors in neutralization assays(Binley 
et al., 2008; Dhillon et al., 2007; Li et al., 2008). This approach was justified by the 
peptide specificity of the most active known V3 loop specific monoclonals (Stanfield et 
al., 2004; Stanfield et al., 2006) but did not detect any broad V3 peptide specific 
activity(Binley et al., 2008; Dhillon et al., 2007; Li et al., 2008). However, a recently 
discovered class of broadly neutralizing antibodies bind to a conformational epitope 
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involving the V3 loop (see below). Given their conformational epitope nature, these 
antibodies were not detected in V3 peptide competition assays.  
Overall, the newly identified antibodies have confirmed that the V3 loop indeed is 
targeted by broadly neutralizing activity. However, these antibodies target 
conformational epitopes rather than continuous peptides. 
Variable Loops V1/2 
Cryo electron microscopy images revealed that the V1/2 loops are located at the tip of the 
trimer(Hu et al., 2011; Liu et al., 2008). V1/2 loop deleted trimers show a more open 
structure and heterogeneity of configuration(Hu et al., 2011).  This suggests that the loops 
most likely contribute to gp120 inter-monomeric interactions (Hu et al., 2011). Crystal 
structures of V1/2 in the context of a scaffold show that the domain folds as four 
conserved anti-parallel β strands with two connecting variable and heavily glycosylated 
loops(McLellan et al., 2011).   
V1/2 loops are not required for viral infectivity but removal leads to increased 
neutralization sensitivity toward V3 and CD4i antibodies(Cao et al., 1997; Liu et al., 
2011). Also, in the course of infection, changes in glycosylation as well as other 
mutations and insertions are believed to mediate escape from autologous 
neutralization(van Gils et al., 2011). Despite their important role in neutralization 
sensitivity, until recently it was not known if variable loops V1/2 are targeted by broadly 
neutralizing antibodies. In fact their strong glycosylation and variability suggested that 
this might not be possible(Pantophlet and Burton, 2006). Similar to the serum 
fractionation results obtained with V3 peptides, V1/2 derived peptides were not able to 
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block broadly neutralizing serum activity(Li et al., 2008). However, recently a group of 
broadly neutralizing antibodies was identified, that penetrates the glycan shield at gp120 
residue N160 and also targets the base of V1/2 (see below, PG9, PG16(Walker et al., 
2009), CH01-04(Bonsignori et al., 2011), PGT141-145(Walker et al., 2011)). Following 
this, several serum studies identified broadly neutralizing sera that target this region. 
These experiments were performed using V loop mutant viruses and adsorption on gp120 
point mutants(Tomaras et al., 2011; Walker et al., 2010). Differences among these 
antibodies in their ability to bind to monomeric gp120 and point mutants suggest that 
there are different approaches to target this epitope(Tomaras et al., 2011). 
Gp41 
After interactions of gp120 with CD4 and the coreceptor, gp41 undergoes conformational 
changes that allow fusion of the virus with the target cell. 
In this process, the N-terminal fusion peptide is inserted into the target cell membrane 
and the two gp41 triple-stranded heptad repeat regions HR-N and HR-C are maximally 
separated. This state is also referred to as the 'prehairpin intermediate'(Chan and Kim, 
1998) and is targeted by the fusion inhibitor Enfuvirtide(Wild et al., 1992). The three 
strands then fold back into three hairpins and form a stable six-helix bundle. This brings 
the viral and target cell membranes into close proximity and establishes a stably locked 
membrane pore(Markosyan et al., 2009). 
Using monoclonal antibodies and polyclonal sera in ELISA based assays, five partly 
overlapping binding clusters were identified as antibody targets on gp41 (reviewed in 
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(Pietzsch et al., 2010b)). Of these, clusters I, II and the membrane proximal region 
(clusters III and IV) have received the greatest attention.  
Cluster I lies in the so-called immunodominant region between the two heptad repeat 
coils. Although this epitope is accessible on pre-hairpin as well as pre-fusion states of the 
gp41 molecule(Frey et al., 2008) no neutralizing antibodies to this epitope were isolated 
to date. Possible explanations for this include poor epitope accessibility on the native 
membrane-bound trimer and inability to inhibit fusion even after antibody 
binding(Finnegan et al., 2002). 
Cluster II lies in the c terminal heptad-repeat region, adjacent to the membrane proximal 
region (MPER). Antibodies to this part of gp41 have also not shown broadly neutralizing 
activity so far. However, the epitope might be involved in binding to the phage display 
neutralizing antibody m44(Zhang et al., 2008). Although binding studies to cell surface 
expressed trimers had suggested otherwise(Finnegan et al., 2002), cluster II antibodies 
seem to bind to gp41 only in the postfusion conformation, which would explain their 
inability to neutralize(Frey et al., 2010). Both of these studies used the same monoclonal 
antibodies and the discrepancies between the results corroborate the need to understand 
more about the native envelope structure in its different fusion states. 
Finally, the MPER is the target of broadly neutralizing antibodies 2F5, 4E10, Z13 and 
10E8 (see below and (Zwick et al., 2001a) (Huang et al., 2012; Pejchal et al., 2009)). 
Inspired by the broad and potent activity of these monoclonal antibodies, serum studies 
have assessed if this epitope is targeted frequently by broadly neutralizing antibodies.  
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One of these studies identified three donors with broad MPER activity among 156 
patients(Gray et al., 2009). This is in contrast to a recent screen of 72 neutralizing serum 
samples that found a significantly higher frequency (27%) of MPER directed broadly 
neutralizing activity(Huang et al., 2012).  
In summary, different areas of the MPER seem to be targeted by broadly neutralizing 
activity in some patients. If other parts of gp41 also are involved in broad neutralization 
is not known so far. A neutralizing phage display derived antibody, m44, binds to a 
conformational gp41 epitope (Zhang et al., 2008). But it is unlikely, that this antibody 
was made in an immune response. Finally, our structural understanding of gp41 is still 
poor. Cryo-electron microscopy studies of native trimers come to different conclusions 
regarding the overall gp41 structure in a tripod configuration(Mao et al., 2012; Zhu et al., 
2006; Zhu et al., 2008) or a compact stalk(Zanetti et al., 2006). Also, although recent 
crystal structures have added the MPER and fusion peptide(Buzon et al., 2010), the 
integration of the MPER into the viral membrane is not well defined. 
In summary, a large fraction of broadly neutralizing serum activity can be adsorbed by 
gp120. In other cases, neutralizing activity is directed to the MPER or could not be 
adsorbed at all. HIV neutralizing serum activity is diverse, even within single patients, 
and the CD4 binding site is often targeted. However, mapping of neutralizing activity has 
to be re-evaluated, since several new neutralizing conformational epitopes involving the 
variable loops have been identified (see below). Also, undefined neutralizing activity still 
remains a significant fraction in several cases and underscores the importance of 
increasing our structural understanding of the native HIV spike. 
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In the future, serum fractionation studies will be able to guide other technologies with 
higher resolution. As the body of monoclonal broadly neutralizing antibodies will grow, 
adsorption studies will be able to evaluate, how far we are from a complete 
deconvolution of broad HIV serum neutralization. 
 
 
 
 
 
 
 
Figure 1; HIV surface trimer with binding regions 
of monoclonal broadly neutralizing antibodies. 
(adapted from (Walker and Burton, 2010)) 
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Monoclonal HIV Neutralizing antibodies 
Up to the year 2009, almost three decades of significant research efforts had yielded only 
four broadly neutralizing monoclonal antibodies, 2F5, 4E10, 2G12 and b12. 
2F5 and 4E10 
Antibodies 2F5 and 4E10 were isolated from patient peripheral blood mononuclear cells 
(PBMCs) using EBV immortalization and electrofusion(Buchacher et al., 1994; Purtscher 
et al., 1994). They target adjacent, continuous epitopes on the membrane proximal region 
(MPER) of gp41(Fig.1)(Muster et al., 1993; Ofek et al., 2004; Zwick et al., 2001a).  
Co-crystallization of both antibodies with peptides revealed that considerable parts of the 
CDR3 regions, in particular the tip, are not interacting with the respective peptide 
epitopes(Cardoso et al., 2005; Ofek et al., 2004), suggesting further interactions between 
the antibodies and the adjacent viral lipid membrane. This has been confirmed for 4E10 
using nuclear magnetic resonance, electron paramagnetic resonance and surface plasmon 
resonance(Sun et al., 2008). Also, mutation studies in 2F5 have shown, that alteration of 
the hydrophobic CDR3 tip markedly reduces neutralizing activity while leaving the 
affinity to the peptide epitope unchanged(Ofek et al., 2010). Together, this data places the 
MPER epitopes of 2F5 and 4E10 into the context of the viral lipid membrane and might 
explain in part why vaccination with gp41 has not been able to elicit this type of 
antibodies yet(Dennison et al., 2009; Dennison et al., 2011; Kim et al., 2007). 
However, the exceptional neutralization breadth of 4E10(Binley et al., 2004) as well as 
impaired infectivity of viral escape variants(Manrique et al., 2007) reflect the 
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conservation of the MPER epitope among the majority of HIV clades and thus makes it 
an important vaccine target (Dennison et al., 2011). 
2G12 
2G12 is a monoclonal antibody directed to gp120. As antibodies 2F5 and 4E10, 2G12 
was isolated from patient PBMCs using EBV transformation and electrofusion(Trkola et 
al., 1996). The epitope of 2G12 lies in the "glycan shield" of the trimer (Fig. 1). A large 
part of the HIV envelope spike surface (50% of its molecular weight) consists of N-
linked glycosylation sites. This "glycan shield" seems to increase and shift in the course 
of infection and escape from autologous antibody responses(van Gils et al., 2011; Wei et 
al., 2003; Wyatt et al., 1998; Wyatt and Sodroski, 1998). As N-linked glycosylation is 
performed by the eukaryotic enzyme machinery in the endoplasmatic reticulum, these 
sites are recognized as "self" by the immune system, which poses another mechanism of 
viral immune evasion. 
Co-crystallization of 2G12 with the disaccharide Manα1-2Man and the oligosaccharide 
Man9GlcNAc2  characterized the interaction of 2G12 with its epitope and identified a 
novel interlocked VH domain-swapped dimer Fab structure(Calarese et al., 2003). This 
structure allows the interaction with a dimer interface region in addition to the two 
classical antigen recognition sites.  
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b12 
In contrast to the above mentioned antibodies, b12 was isolated from an HIV patient 
using random heavy and light chain pairing in a phage display library(Burton et al., 1991; 
Burton et al., 1994). Therefore, structural insights derived from this antibody must be 
interpreted carefully.  
Despite this limitation, b12 has introduced the CD4 binding site as an important target of 
broadly neutralizing serum responses (Fig. 1). Docking the crystal structure of b12 onto 
gp120 in the CD4 bound conformation(Saphire et al., 2001) and direct co-crystallization 
(Zhou et al., 2007)have defined a footprint of the b12 binding area on gp120.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 21 
Application of neutralizing antibodies 
Protection through transfer of neutralizing antibodies 
The discovery of antibodies 2G12, 4E10, 2F5 and b12 has impacted our structural 
understanding of the HIV surface trimer and pointed out possible vaccine targets. 
However, their direct value as protective or therapeutic agents against HIV has also been 
extensively assessed in vivo.  
One of the first passive transfer studies in macaques used bulk IgG instead of monoclonal 
antibodies. The polyclonal IgG had been isolated from macaques that had developed a 
neutralizing response after being infected with a variety of clade B strains (Shibata et al., 
1999). Passive immunization followed by intravenous challenge with SHIVDH12 showed 
that complete protection was possible but dose dependent and only conferred by IgG that 
showed in vitro neutralization against the challenge virus(Shibata et al., 1999). 
Protection against intravenous challenge was also achieved in macaques using HIVIG 
and monoclonal antibodies 2G12 and 2F5 (Mascola et al., 1999). However, in order to 
reach sterile protection, a combination of these three reagents was required and passive 
immunization with either 2G12, 2F5 or HIVIG alone was not sufficient in the setting of 
intravenous virus challenge(Mascola et al., 1999).  
At the same time, passive transfer of monoclonal antibodies 2G12 or b12 alone mediated 
protection against vaginal virus challenge(Mascola et al., 2000; Parren et al., 2001).  
Finally, the vaginal application of a total of 5mg of the monoclonal antibody b12 was 
able to protect 4/4 macaques against vaginal SHIV challenge(Veazey et al., 2003).  
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In summary, these studies have lent support to the model of antibody based protection 
from intravenous and mucosal HIV challenge and thus invigorated efforts to find a way 
to elicit these classes of antibodies with a vaccine. At the same time, high concentrations 
of antibodies were required in order to reach protective levels due to the relatively limited 
potency of the antibodies used. This limitation at the time diminished hopes to widely use 
these antibodies as reagents in passive immunization or even reach sufficient levels by 
vaccination(Mascola and Nabel, 2001).   
As discussed below, the recent identification of highly potent HIV antibodies by us and 
other groups has changed the potential of achieving HIV protection by vaccination or 
passive immunization dramatically (Balazs et al., 2012). So far we still are far from using 
these new antibodies in the clinical setting as protective reagents against HIV or even 
achieving this activity by active immunization. However, the unprecedented potency and 
breadth of these new reagents and modified versions thereof(Song et al., 2010) as well as 
the growing number of neutralizing target epitopes make these goals significantly more 
feasible as just a few years ago. 
Treatment approach of established HIV infection with broadly neutralizing 
antibodies 
In addition to protection against viral challenge, monoclonal antibodies potentially could 
offer modification or even reduction of an established HIV infection.  
This was first studied in 14 antiretrovirally treated HIV infected subjects whose viral 
isolates were highly sensitive to broadly neutralizing antibodies(Trkola et al., 2005). 
Antibodies 2G12, 2F5 and 4E10 were passively administered over a period of 11 weeks 
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during which antiretroviral treatment was paused. Overall, the mixture of antibodies was 
able to delay viral rebound in 2/8 chronically infected participants(Trkola et al., 2005). In 
acutely infected individuals the viral rebound was delayed in 6/6 cases(Trkola et al., 
2005), although this is hard to interpret because these cases were not internally controlled 
for viral rebound without antibody treatment. Nevertheless, the more pronounced delay 
of rebound in acutely infected individuals might be attributable to a less diverse viral 
population in recently infected patients, leading to a reduced likelihood of preexisting 
escape mutants to the respective antibodies. 
There are numerous limitations to this study including the fact that b12 as one of the 
more potent monoclonal antibodies known at that time was not included and plasma 
levels of 2F5 and 4E10 were significantly lower than for 2G12. Resistance to 2G12 was 
acquired in the majority of cases but to 2F5 and 4E10 in only 3/14 and 0/14 of the cases 
respectively. Therefore, 2F5 and 4E10 might not have been present in concentrations 
sufficient to exert selective pressure.  
Nevertheless, this study has introduced a potential therapeutic application of broadly 
neutralizing antibodies in humans and proven that this type of antibodies can exert 
selective pressure in an established HIV infection. 
Similar to HIV protection by passive antibody administration (see above), HIV antibody 
therapy has to be completely reassessed since the recent discovery of highly potent 
broadly neutralizing antibodies. First experiments in humanized mice (Klein et al., 
2012b) have yielded prolonged control of viral loads in animals treated with a 
combination of 5 antibodies. 
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This finding transformed the longstanding dogma that HIV envelope spike diversity and 
capacity to mutate would preclude any attempt to use it as a target in HIV antibody 
treatment. Several studies are now underway to investigate how this treatment compares 
to traditional HAART and if these two treatment modalities might be combined in 
humans. 
In summary, until 2009 three decades of intense research efforts had produced only 4 
broadly neutralizing antibodies using EBV immortalization, electrofusion and phage 
display libraries. These antibodies have provided some insight into possible vaccine 
targets and in vivo applications of monoclonal antibodies including prevention and 
treatment. However, the fact that broad neutralizing serum activity against HIV is 
developed in around 10% of millions of HIV patients demanded a systematic 
investigation of this activity.  
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Memory B cells as a target to study HIV B cell responses 
The thrust of our study was to design a way to efficiently and systematically study the B 
cell response against HIV in patients with broadly neutralizing serum activity. This 
would allow us to learn more about possible vaccine targets and isolate highly potent 
monoclonal antibodies for possible clinical applications. For this, we started with a large 
screen of 470 serum samples from HIV patients with low to intermediate viral loads. In 
accordance with previous studies (Doria-Rose, 2010; Gray et al., 2011; Mikell et al., 
2011; Sather et al., 2008; Simek et al., 2009; Stamatatos et al., 2009; Walker et al., 2010) 
we found that 5% of patients display broadly neutralizing serum activity. But where is 
this activity generated and which cells would be appropriate to study in order to 
characterize the monoclonal components of polyclonal serum activity? 
Germinal Centers 
Specificity and high affinity of antibodies are created in germinal center reactions(Berek 
and Milstein, 1987; Eisen and Siskind, 1964; Jerne, 1951; McKean et al., 1984; Weigert 
et al., 1970). Initially believed to be the anatomical site of lymphocyte production, 
germinal centers change in size and mitotic activity following injection of foreign 
antigens(reviewed in (Nieuwenhuis and Opstelten, 1984)). This mitotic activity was 
attributed to dividing B cells(Nieuwenhuis and Opstelten, 1984), which connected 
germinal center formation with the development of antigen specific B cell responses. 
Somatic hypermutation and affinity maturation of immunoglobulins are key elements of 
antigen specific B cell responses (Berek and Milstein, 1987; McKean et al., 1984; 
Weigert et al., 1970) and are located at the site of germinal center reactions(Berek et al., 
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1991; Jacob et al., 1991b). In vivo studies(Allen et al., 2007a; Allen et al., 2007b; Hauser 
et al., 2007; Schwickert et al., 2007) provided insight into the dynamic structure of the 
germinal center reaction: 
In the initiation of a germinal center reaction, mature naive IgM+ B cells are recruited 
based on their antigen affinity and subsequently undergo several rounds of affinity 
maturation of their immunoglobulin genes(Berek et al., 1991; Jacob et al., 1991a; Jacob 
et al., 1991b; Nieuwenhuis and Opstelten, 1984; Victora and Nussenzweig, 2012). 
Migrating back and forth between dark and light zones of the germinal center, the B cells 
proliferate and mutate in the dark zone before returning to the light zone in order to bind 
to antigen presented by follicular dendritic cells and receive stimulation through T helper 
cells(Allen et al., 2007a; Allen et al., 2007b; Hauser et al., 2007; Schwickert et al., 2007). 
After probing the affinity of the mutated B cell receptor (BCR), the B cells then return to 
the dark zone for a further round of proliferation and mutation before returning to the 
light zone again(Victora and Nussenzweig, 2012).  
The key enzyme involved in the process of somatic hypermutation as well as class switch 
recombination in the dark zone is Activation Induced Deaminase (AID), which 
deaminates cytidine residues in the VDJ and switch regions of Ig genes(Neuberger et al., 
1999; Nussenzweig and Nussenzweig, 2010; Pavri and Nussenzweig, 2011). The 
mutation rate of AID is approximately 10-3 per base pair per cell division and its activity 
targets transcribed regions displaying ssDNA, therefore posing a potential threat to other 
parts of the B cell genome(Muschen et al., 2000; Nussenzweig and Nussenzweig, 2010; 
Odegard and Schatz, 2006; Pasqualucci et al., 2001; Shen et al., 1998). One could 
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speculate, that AID mediated somatic hypermutation might partly explain increased rates 
of B cell lymphomas during chronic infections, such as HIV(Gaidano et al., 2003). 
Memory B cells 
The outcome of a germinal center reaction are antibody secreting plasma cells as well as 
memory B cells(Blink et al., 2005; Phan et al., 2006), both of which carry 
immunoglobulins with high affinity to their antigen. Post germinal center memory B cells 
are non-cycling cells that do not require stimulation by antigen in order to persist for long 
periods of time(Maruyama et al., 2000). However, they expand rapidly in response to 
antigen and develop into plasma cells that reside in the bone marrow and produce large 
quantities of antibodies(Dorner and Radbruch, 2005, 2007). 
Given their high density of specific surface Ig, memory B cells potentially are ideal 
targets to investigate the B cell response against a specific antigen(Greenstein et al., 
1980; Hayakawa et al., 1987; McHeyzer-Williams et al., 1991; Scheid et al., 2009b).  
Using fluorescently linked antigens, we proposed to first identify the HIV envelope 
specific memory B cell response in donors with high levels of broadly neutralizing serum 
activity. We then planned to use fluorescence activated cell sorting (FACS) of single 
antigen specific memory B cells, followed by single cell reverse transcription and 
specific immunoglobulin gene amplification(Wardemann et al., 2003). This would allow 
us to analyze, clone and potentially reproduce the immunoglobulins of the HIV envelope 
specific B cell population on a monoclonal level.   
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Chapter 2 
Broad diversity of anti-gp140 memory antibodies 
 
Characteristics of anti-gp140 memory antibodies 
We characterized the antibodies produced by memory B cells purified from the blood of 
six patients with broadly neutralizing anti-HIV antibodies and viral titers ranging from 
49-12,709 copies/ml. One of the patients was a non-progressor(Binley et al., 2004; Cao et 
al., 1995), three were elite controllers(Binley et al., 2004; Deeks and Walker, 2007; 
Walker, 2007), one a slow progressor(Binley et al., 2004; Li et al., 2007), and one was 
infected two years ago(Scheid et al., 2009a).  
Artificially trimerized YU2 gp140 protein composed of gp120 and cytoplasmic tail 
truncated gp41 was used to identify and purify HIV specific B cells because it is believed 
to resemble the envelope spike in some respects(Farzan et al., 1998; Pancera et al., 2005; 
Yang et al., 2000; Yang et al., 2002; Zhu et al., 2006). Most importantly, we were able to 
adsorb the anti-gp120 and -gp41 IgG antibodies in the serum of the patients with 
trimerized YU2-gp140 (Fig. 2).   
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Figure 2; Serum adsorption by 
YU2-gp140 trimer and binding 
to control monoclonal 
antibodies.  ELISA results of 
serum IgG tested for binding to 
gp140, gp120 and gp41 before 
and after adsorption with YU2 
gp140 trimer. Patients 1-4 are 
represented in red, green, brown 
and blue respectively. 
 
 
Small numbers of B cells that bound the gp140 trimer were readily detected in the IgG+ 
memory B cell compartment in the patients but not in uninfected controls (Fig. 3a). 
Individual gp140 binding memory B cells were purified by cell sorting, and Ig heavy and 
light chains cloned from single cell cDNA libraries(Scheid et al., 2009b; Tiller et al., 
2008). We were able to amplify an average of 114 matching Ig heavy and light chain 
genes from each of four HIV infected individuals and smaller numbers from two 
others(Scheid et al., 2009a). 
In contrast to random antibody cloning from memory B cells(Mietzner et al., 2008; Tiller 
et al., 2007), and to the antibodies isolated from B cells that did not bind to gp140 from 
the same subjects, we found many clonally related antibodies in the gp140 binding B cell 
repertoire of all six HIV infected individuals (Fig. 3b and Table 1).  The number of B cell 
clones varied among patients from 22-50, and each clone was expanded to varying 
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degrees ranging from 1-39 family members (Fig. 3b and Table 1).  In all cases the 
majority of the antibodies derived from gp140 binding memory B cells belonged to 
clones with more than one member and in patient #2 all of the 141 antibodies were 
members of 22 expanded families related by somatic mutations (see below).  The finding 
that most of the antibodies isolated from the four more complete patients belonged to 
expanded clones suggested that we captured a significant fraction of the gp140-reactive 
memory B cell repertoire. 
 
Figure 3; Anti-gp140 antibody 
cloning.  a, Flow cytometry plots 
of peripheral blood mononuclear 
cells from four HIV patients 
stained with anti-CD19 and 
biotin-gp140. b, Distribution of 
gp140 binders and non-binders 
among all antibodies cloned. c, 
Igk and Igl expression among all 
gp140 binding antibodies. The 
number in the center of the pie is 
the number of antibodies, slices 
are unique clones and 
proportional to clone size. d, 
gp140 binding ELISA for 
antibodies from gp140 binding 
cells from patient-1, -2, and non-
binders from patient 2. The red 
line shows b12(Burton et al., 
1991) control, green line is a 
negative control 
mGO53(Wardemann et al., 
2003). 
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Individual antibodies were expressed as complete IgG molecules by transfection and 
tested for reactivity to gp140 by ELISA. 86% of all of the antibodies cloned from gp140 
binding B cells were gp140 reactive (Fig. 3B).  In contrast, none of the 51 antibodies 
obtained from the non-gp140 binding memory B cells from two of the same patients were 
gp140 specific (Fig. 3D and Table 1).  In total, out of 501 cloned antibodies we obtained 
432 antibodies that bound to gp140, and they belonged to 132 different B cell clones  
(Table 1).  The expanded clones of gp140 binding B cells contained antibodies that were 
related by mutation with a maximum number of 66 mutations separating the individual 
clonal relatives (Table 1, and see below). 
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Table 1; IgH and IgL chain gene sequence information and antibody reactivity and neutralization 
assay results of anti-gp140 antibodies. ND indicates not determined. The number of clone members with 
100% IgH and IgL chain gene sequence homology is indicated and clonal relatives with various degrees of 
somatic mutations are shown in the same color. a-e, Antibodies from gp140-reactive IgG B cells from 
patients 1-6. f-g, Antibodies from gp140 non-reactive IgG B cells from patients 2 and 3 
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Figure 4; Anti-gp140 antibody repertoire. Top line indicates patient number and gp140 binding. 
IgGm are previously published controls(Tiller et al., 2007). Each clone is represented once 
irrespective of clone size, or somatic variants.  a, VH repertoire analysis. b, IgH CDR3 length. c, 
Igk repertoire comparing Vk and Jk. d, Graphs show numbers of mutations per antibody for VH and 
Vk grouped by patient or VH (right) grouped by epitope.  Red stars indicate p values ≤0.001. P 
values were calculated by comparison to the pool of gp140 non-reactive antibodies except those 
below the lines, which refer to the paired samples.  
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When compared to IgG antibodies derived from non-gp140 binding B cells from the 
same patients or IgG+ memory B cells from historical controls(Tiller et al., 2007) the 
gp140 binding antibodies were enriched for VH1(Huang et al., 2004), Igk vs. Igl, and Jk2 
or Jk5 (Figs. 3c and 4a, b and c).  Individual patients showed longer or more charged IgH 
CDR3s but these features were not found in all of the patients (Fig. 4b).  An unexpected 
finding was that anti-gp140 antibodies were highly mutated when compared to non-
gp140 binding antibodies from the same patients or randomly cloned IgG memory 
antibodies from historical controls (Fig. 4d).  This difference in mutation frequency was 
found for both VH and Vk and was highly significant whether we included all antibodies 
or counted individual clones only a single time (Fig. 4d)(Scheid et al., 2009a).  We 
conclude that anti-gp140 memory B cells are highly selected post-germinal center cells 
skewed to Igk and VH1 usage.  The exceptionally high level of mutation found in these 
antibodies may reflect chronic B cell immune responses to HIV with persistent somatic 
hypermutation and selection. Previous studies have shown that re-entry of memory B 
cells into germinal centers occurs in humans(Bende et al., 2007). In the case of HIV, the 
immune system is confronted with a chronic and constantly mutating pathogen, which 
could lead to repeated recruitment of memory cells into germinal center reactions, thus 
leading to ongoing AID mediated somatic hypermutation. 
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Epitopes recognized by anti-gp140 memory antibodies 
To map the antigenic specificity of the gp140 binding antibodies we initially performed 
ELISA experiments with purified gp120 and gp41.  We found that 70% of the gp140 
antibodies bound to gp120 and 30% were gp41 specific (Fig. 5a, b, and c).  Thus, the 
majority of the antibodies cloned from gp140 binding memory B cells in patients with 
broadly neutralizing anti-HIV antibodies are directed to gp120.  
Anti-gp41 antibodies were further screened against a peptide library consisting of 
overlapping 15mers including the membrane proximal region that binds to two broadly 
neutralizing anti-gp41 monoclonal antibodies 2F5 and 4E10(Muster et al., 1993; Zwick et 
al., 2001a).  None of the 131 anti-gp41 antibodies assayed bound to the membrane 
proximal peptides and only five antibodies bound to peptides corresponding to the 
previously reported immunodominant region of gp41(Xu et al., 1991)(Table 1).  We 
conclude that the majority of the gp41 antibodies produced by gp140 binding memory B 
cells in patients with broad serum neutralizing activity recognize conformational 
determinants and that antibodies to the membrane proximal region are difficult to detect 
in the gp140 trimer binding B cells in these patients despite the fact that both 2F5 and 
4E10 bind to the trimer and that the trimer adsorbs the majority of the anti-gp41 
antibodies in the patients serum (Fig. 2, and (Scheid et al., 2009a)).    
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Figure 5; Anti-gp140 mapping by ELISA. a,  Pie charts show distribution of anti-gp120 and anti-
gp41 antibodies.  b,  Pie charts show distribution of antibodies binding to CD4bs, CD4i, VL, and 
gp120core (Core). c, Representative ELISA results. anti-VL, 447-52D(Gorny et al., 1992) green, 2F5 
anti-gp41(Buchacher et al., 1994) blue, b12 anti-CD4bs(Burton et al., 1991) red, neg. control purple 
(Wardemann et al., 2003), anti-Core 4-221 black, dashed lines: 2-59 anti-VL green, 3-384 anti-gp41 
blue, 2-1262 anti-CD4bs red. d, Competition ELISA for binding to gp120; patient-1 (green), -2 (blue), 
-3 (orange), and -4 (purple). Each dot indicates the IC50(Scheid et al., 2009a). Red arrow shows self-
inhibitory activity. b12 black, 447-52D open circle.  
The specificity of the anti-gp120 binding antibodies was further mapped using a 
collection of mutant proteins: gp120D368R interferes with binding to CD4 and all known 
anti-CD4 binding site (anti-CD4bs) antibodies including b12(Olshevsky et al., 1990; 
Pantophlet et al., 2003; Roben et al., 1994; Thali et al., 1991); gp120I420R interferes with 
CD4 induced co-receptor binding site antibodies (anti-CD4i) including 17b(Thali et al., 
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1993); gp120core lacks the variable loops (VLs) and interferes with anti-VL and CD4i 
antibodies(Kwong et al., 2000; Kwong et al., 1998; Wyatt et al., 1998).  Antibodies that 
bound to gp120, gp120core, gp120I420R but not to gp120D368R were classified as CD4bs 
directed.  Similarly, those that bound to gp120, gp120I420R but not to gp120core were 
classified as anti-VL antibodies, and those that bound to gp120 and gp120D368R, but not to 
gp120I420R were classified as anti-CD4i antibodies. Anti-CD4bs, -CD4i, and -VL 
antibodies were found in all 4 of the more complete patients but their relative 
representation varied significantly between patients (Fig. 5b).  Among all anti-gp140 
antibodies anti-CD4bs made up 9%, anti-CD4i 16% and anti-VL 27% (Fig. 5b).  All of 
these antibodies were also screened for binding to a library of overlapping 15mer 
peptides covering all of gp120.  Only three of the anti-gp120 antibodies bound to linear 
peptides and all of these bound to the region within the V3 loop that is also targeted by 
the previously described antibody 447-52D(Gorny et al., 1992)(Table 1).  
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Affinity of anti-gp140 antibodies 
To examine the kinetic binding properties of the anti-CD4bs, -CD4i and -VL antibodies 
to gp140 we performed surface plasmon resonance experiments with gp140 trimer 
comparing the binding of 13 such antibodies with the b12 anti-CD4bs monoclonal  
(Fig. 6 and Table 2).  We found that all of the antibodies had rapid association and slow 
dissociation constants with KD’s ranging from 10-8-10-11 M; b12 performed at the lower 
end of the spectrum with a KD of 1.2X10-8 M (Fig. 6 and Table 2). Thus, the gp140 
directed IgG memory B cells obtained from the patients studied expressed high affinity 
antibodies specific for the CD4bs, the CD4i site and the VLs and there was no 
immunodominant epitope. 
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Figure 6; Surface plasmon resonance measurements for interaction between selected antibodies 
and gp140. Graphs show antibody dissociation curves over time. The starting concentration of gp140 
was 25-50µg/ml and the different curves represent 1:2 dilutions of the starting material. The X-axis 
shows time in seconds and the Y-axis shows the response rate. The antibodies are indicated above each 
graph. Red squares indicate anti-CD4bs, blue circles anti-gp120core, green triangle anti-CD4i and 
yellow triangle anti-VL antibodies. 
 
 
Table 2; Affinity measurements of b12 and selected patient antibodies by surface plasmon 
resonance. Stars indicate cases in which the sensorgrams are virtually flat during the dissociation phase. 
Off-rates might therefore be even slower than the ones listed. Epitopes against which the affinities were 
measured are indicated above. (M=Mol/liter; s=seconds) 
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Anti-gp120core antibodies. 
In addition to anti-CD4bs, -CD4i, and -VL antibodies we found a group of antibodies that 
bound to gp120, gp120core, gp120D368R, and gp120I420R that we refer to as anti-gp120core 
(Fig. 7).  These antibodies also bound to gp120368/370AA harboring a double mutation, 
which also interferes with binding to many of the known anti-CD4bs antibodies and 
CD4(Li et al., 2007; Olshevsky et al., 1990).  
 
Figure 7; Binding of anti-gp120core antibodies to gp120, gp120D368Rand gp120D368A/E370A.  
Anti-Core antibodies from patients 1-4 and 6 were tested in ELISA for their binding to YU2 gp120, 
gp120D368Rand gp120D368A/E370A. Red lines indicate binding to gp120, blue to gp120D368R and 
green to gp120D368A/E370A. B12 is shown as a control. 
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Figure 8; Effect of deglycosylation 
on BAL gp120 binding. a, Gel 
electrophoresis and Coomassie blue 
staining or Western blot with LCA 
and DCA lectin of BAL gp120 and 
aglyco-BAL-gp120. b, 
Representative ELISA results 
comparing binding to gp120 and 
aglyco-gp120 for control antibody 
2g12. The red line indicates gp120 
binding and green line indicates 
aglyco-gp120 reactivity. Antibody 
concentration is shown on the X 
axis and OD405 on the Y axis.  c, 
Binding to gp120 (red) or aglyco-
gp120 (green) as measured by 
ELISA under saturation conditions 
for all neutralizing antibodies from 
patients 1-4. Epitopes, patient 
source, antibody number and 
relative (see above) OD405 are 
indicated. Stars show antibodies 
sensitive to deglycosylation. 
Anti-gp120core antibodies make up 18% of all anti-gp140 antibodies cloned from gp140 
binding memory B cells varying between patients from 3-35% of the repertoire (Fig. 5b 
and Table 1).  In order to determine how many of these antibodies are glycan-directed we 
compared binding to wild type and deglycosylated BAL gp120.  None of the anti-
gp120core antibodies were sensitive to deglycosylation (Fig. 8).  Therefore, these 
antibodies are not predominantly directed to sugar moieties on gp120. In addition, none 
of the anti-gp120core antibodies bound to a peptide library consisting of overlapping 
15mers of gp120.  
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To further examine the properties of the anti-gp120core antibodies we performed inhibition 
ELISA experiments using biotin labeled neutralizing antibodies to the CD4bs (b12 and 1-
64), or CD4i (1-182), or the V3L (1-79) or a representative member of the gp120core 
specific group (2-491)(Binley et al., 2004) (Fig. 5d and Table 1).  As expected the results 
for the two anti-CD4bs antibodies b12 and 1-64 were similar and both were inhibited by 
other neutralizing anti-CD4bs antibodies but not by CD4i or VL specific antibodies (Fig. 
5d).  In contrast, neutralizing anti-CD4i, 1-182, was inhibited by all of the neutralizing 
anti-CD4bs antibodies, but only by 50% of the other anti-CD4i (possibly due to 
differences in affinity) and 29% of the anti-VL antibodies (Fig. 5d and Table 1).  The 
selected neutralizing anti-V3L antibody was strongly inhibited by the other anti-V3L 
antibodies and not by anti-CD4bs, anti-CD4i, or other neutralizing anti-VLs that were not 
V3L-NNNTRKSINIGPGRA peptide specific (Fig. 5 and Table 1).  These results are 
consistent with structural and physiologic data suggesting that the CD4bs is in close 
proximity to the CD4i site and that the conformation of the CD4i site is dependent on the 
CD4bs(Kwong et al., 1998; Liu et al., 2008; Rizzuto et al., 1998; Thali et al., 1993; Wyatt 
et al., 1998). 
Anti-gp120core antibodies resembled b12 and CD4bs antibodies in that they inhibited the 
binding of the selected anti-gp120core, anti-CD4bs, and anti-CD4i, but they did not inhibit 
binding of the anti-V3L antibody.  Conversely, the 2-491 anti-gp120core antibody was 
inhibited by the other anti-gp120core and the anti-CD4bs antibodies (Fig. 5d and Table 1).  
However, only three out of thirteen of the anti-CD4i antibodies and none of the seven 
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anti-VL antibodies inhibited binding of the anti-gp120core (Fig. 5d).  The affinity of anti-
gp120core antibodies to gp140 is similar to that of the anti-CD4bs antibodies (KD’s ranging 
from 2X10-8 to 4.8X10-10 M, Fig. 6 and Table 2).  In addition, both classes of antibodies 
show similar affinities to gp120 and gp120core (Table 2).  We conclude that anti-gp120core 
antibodies recognize an immunogenic epitope in the vicinity of the CD4bs and CD4i 
sites.  
In a follow up study we were able to further characterize the gp120core epitope by using 
screening of gp120 alanine mutants(Pietzsch et al., 2010a). ELISA binding assays with 
the panel of gp120core antibodies we had isolated (Table1) revealed, that this group of 
antibodies shares an epitope at the outer/inner domain junction on gp120(Pietzsch et al., 
2010a). Furthermore, in experiments using mutant BAL HIV pseudovirus this epitope 
was essential for viral infectivity(Pietzsch et al., 2010a). 
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HIV neutralizing activity 
To examine the neutralizing activity of the memory B cell antibodies we measured their 
ability to inhibit infection of TZM-bl cells by Env pseudovirus variants(Montefiori, 
2005),(Binley et al., 2004).  Our panel included one isolate each from clades A and C as 
well as a group of clade B viruses with different levels of resistance to known 
neutralizing antibodies(Li et al., 2005; Li et al., 2006; Montefiori, 2005) ranging from 
tier-1 strains like SF162.LS that are easily neutralized to tier-2 strains like TRO.11 which 
are not neutralized even by potent broadly neutralizing anti-CD4bs antibody b12(Li et al., 
2005)(Fig. 9 and Table 3).  Although most of the antibodies were tested against the entire 
panel, some that did not neutralize any of the tier 1 viruses were not tested against tier 2 
viruses (Fig. 9 and Table 3). Finally, purified serum IgG from the patients was assayed on 
the same viruses for comparison (Fig. 9 and Table 3). Purified IgG neutralized the 
majority of strains tested, but the activity was most pronounced for the more easily 
neutralized tier-1 HIV variants while high concentrations of serum IgG were required for 
the more resistant strains  (Fig. 9 and Table 3).  Interestingly, 76% of all anti-gp120s and 
none of the anti-gp41 clonal families showed neutralizing activity (Fig. 9 and Table 3). 
All anti-CD4bs and 88% of all anti-gp120core antibodies showed some neutralizing 
activity (Fig. 9 and Table 3).   
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Figure 9; Anti-gp140 antibody neutralizing activity. Source of antibodies at the top.  a, Pies show 
neutralizing antibodies colored, non-neutralizers grey. Epitopes are indicated. Slices are proportional 
to clone size. Number of antibodies in center. b, IC50 for individual antibodies to gp41, CD4bs, 
CD4i, gp120core, VLs. Colors of dots correspond to pies above. Stars indicate control antibodies b12, 
17b and 447-52D(Gorny et al., 1992). c, Neutralizing activity of pooled anti-gp140s; d, Neutralizing 
activity of IgG.  b, c, and d, Y axis shows the antibody concentration in mg/ml required to achieve 
IC50. The individual viruses on the X axis are indicated below. 
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Table 3; In vitro Tzm-bl neutralization assay. Numbers indicate IC50s for the specific monoclonal 
antibody, serum IgG, or pooled antibodies in the Tzm-bl assay measuring inhibition of infection by the 
indicated viral strains. X indicates activity that did not reach IC50 values at the concentration tested. a-
d, patients 1-4 and previously described control antibodies; e, patients 5, 6. 
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Of a total of 64 independent clonal families of neutralizing antibodies 22 were anti- 
gp120core, 18 were anti-CD4bs, 16 were anti-CD4i, and 8 were anti-VL including all three 
of anti-V3L antibodies (Fig. 9 and Table 3).  As a group, the antibodies to the CD4bs and 
gp120core showed the highest levels of neutralizing activity with rare antibodies showing 
activity against the more resistant tier-2 viruses at high concentrations (Fig. 9 and Table 
3). Although the anti-V3L antibodies showed cross-clade neutralizing activity, and one of 
them neutralized tier-2 viruses at high concentrations, most of the anti-VL antibodies 
were more restricted (Fig. 9 and Table 3).  Neutralizing activity was also found in the 
anti-CD4i antibodies but only three of these antibodies reached IC50 values against the 
more difficult to neutralize tier-2 viruses  (Fig. 9 and Table 3).   
Serum antibody adsorption studies found that neutralization of tier-2 viruses was 
predominantly achieved by anti-CD4bs with a smaller variable contribution from anti-
CD4i and un-identified antibodies.  However, as mentioned above, the resolution in such 
studies is limited and they cannot define the nature or number of antibodies to a specific 
site(Binley et al., 2008; Dhillon et al., 2007; Li et al., 2007; Li et al., 2008; Sather et al., 
2008).  We found no case where a single monoclonal antibody or class of antibodies in 
memory B cells accounts for all of the neutralizing activity in serum (Fig. 9 and Table 3).  
Individual antibodies showed variable levels of activity against different viruses.  For 
example in patient #1, the clade-C virus MW965.23 was neutralized by gp120core 
antibodies 1-621 and 1-705 and VL antibody 1-79, with anti- gp120core 1-705 showing the 
highest activity  (Fig. 9 and Table 3).  In contrast, 1-621 did not neutralize the clade-B 
virus Bal.26, whereas 1-79 did and was superior to 1-705 (Fig. 9 and Table 3). Similarly 
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in patient #2, the clade-A virus DJ263.8 is neutralized by anti-CD4bs 2-470, anti-VL 2-
59 but not anti-VL antibody 2-1261, whereas the same anti-VL antibody neutralized the 
clade-B tier-2 virus RHPA4259.7, but neither 2-470 nor 2-59 reached IC50 against this 
virus (Fig. 9 and Table 3).  In conclusion, some degree of neutralizing activity was 
common among gp120 specific memory antibodies. These antibodies recognized a broad 
array of epitopes and neutralizing activity was heterogeneous for different viral isolates.   
Memory B cells are long-lived cells and their antibodies reflect an individuals immune 
responses over time.  Some of these cells differentiate into plasma cells that secrete 
antibodies but the relative contribution of any given memory B cell to the plasma cell 
compartment is unknown and therefore a pool of cloned memory B cell antibodies cannot 
be compared directly to serum.  Nevertheless, we created pools of all antibodies for each 
individual patient and compared the pools to purified serum IgG for neutralization (Fig. 9 
and Table 3).  The pools contained equal concentrations of each of the anti-gp140 clones 
irrespective of clone size (Fig. 2), potential competition for epitope binding (Fig. 5) or  
neutralizing activity (Fig. 9).   
Purified IgGs from all four patients studied neutralized nearly all of the tier-1 viruses and 
the corresponding pools of the recombinant antibodies were also active against these 
viruses (Fig. 9 and Table 3).  In addition, some of the antibody pools neutralized viruses 
that were not neutralized by the IgG fraction.  For example, pt4 purified IgG did not 
reach an IC50 against SS1196.1 or 6535.3 (tier-2), but these viruses were neutralized by 
recombinant antibodies 4-42, 4-8 and 4-433 and by pooled antibodies (Fig. 9 and Table 
3).   
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In contrast, much higher concentrations of the patients’ serum IgG were required for tier-
2 neutralizing activity ranging from 49-1258 mg/ml.  Consistent with the more stringent 
requirements for tier 2 neutralization, only the pooled monoclonal antibodies from patient 
1 and 4 reconstituted this type of activity and only at high concentrations (Fig. 9 and 
Table 3).  For example, RHPA4259.7 and TRO.11 were neutralized by 1.1 mg/ml of the 
patient 1 pool (pool of 21 antibodies each at maximum concentration of 52 µg/ml). 
Similarly, the TRO.11 virus was neutralized by the pooled antibodies from patient 4 at 
1.4mg/ml (pool of 50 antibodies).  In both cases individual antibodies did not reach IC50 
values against these viruses but several antibodies showed low levels of activity (Fig. 9 
and Table 3).  In conclusion, the memory antibody compartment contains a large mixture 
of anti-HIV neutralizing antibodies combinations of which can reach the breadth of 
activity found in the serum but only at high concentrations. 
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Discussion 
Since the discovery of HIV numerous monoclonal antibodies to the envelope protein 
have been produced by random cloning of heavy and light chains in phage display 
libraries or by selection of antibody secreting hybridomas, but until recently only a few 
highly active broadly neutralizing antibodies have been obtained(Burton et al., 2005; 
Karlsson Hedestam et al., 2008; Mascola, 2007; Pantophlet and Burton, 2006; Zolla-
Pazner, 2004). Among these b12(Burton et al., 1991), 2F5 and 4E10(Buchacher et al., 
1994; Zwick et al., 2001a), and 2G12(Trkola et al., 1996) had received the greatest 
attention because of their unique breadth and potency in vitro and in vivo.  
The thrust of this work was to establish a new and highly efficient way to identify and 
characterize the HIV envelope specific memory B cell repertoire in patients with broadly 
neutralizing antibodies. For the first time we were able to delineate comprehensively the 
immunoglobulin gene features as well as size and diversity of this particular B cell 
repertoire. 
In contrast to previous models, we found that the antibody repertoire against env is not 
limited to a few immunodominant regions but rather targets a diversity of epitopes on 
gp120 and gp41. The epitopes we mapped include a new class of neutralizing antibodies 
to gp120core, which targets a region at the outer /inner domain junction of gp120. This 
epitope is essential for viral infectivity and thus possibly has implications in vaccine 
design.  
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We also found, that neutralizing activity in the HIV env directed B cell response is 
diverse. If broad neutralization in these patients is achieved by targeting multiple 
epitopes, then a vaccine that phenocopies such a response should also include several 
epitopes. 
However, only in two patients we reconstituted the neutralization breadth of purified 
serum IgG, and only at high concentrations. This finding implies that we still were 
missing parts of the serum antibody repertoire of these patients.  
Possible reasons for this limitation include the choice of bait used in the staining and 
sorting of B cells. Neutralizing activity directed to epitopes not displayed on YU2 gp140 
would not be recovered with our methods. Furthermore, broadly neutralizing memory B 
cells could be very rare, making a more targeted bait necessary. We did isolate many 
clonally related B cells, suggesting that we captured a significant fraction of env specific 
B cell clones. However, we might not have identified rare clonal members of expanded B 
cell families with increased neutralizing activity.   
Memory and plasma B cell compartments are intertwined and we expect to capture a 
significant fraction of the serum response against HIV env by investigating memory B 
cells. But so far no study has portrayed a human antigen specific B cell response with this 
resolution. Therefore, differences between the antibody secreting plasma cell 
compartment and the memory B cell compartment provided another possible explanation 
for the lack of completely reconstructing the serum response in the investigated patients. 
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A high level of somatic hypermutation is another feature of this antibody compartment. 
HIV is a chronic infection with a mutating virus, and ongoing germinal center reactions 
or even recall of memory B cells into germinal centers might play a role in this process. 
Our approach relies on PCR amplification and therefore primer binding to supposedly 
conserved elements in the immunoglobulin genes. Therefore, hypermutation of these 
conserved regions could limit our ability to fully capture the B cell response in the 
patients studied. 
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Chapter 3 
Sequence and Structural Convergence of Broad and Potent 
HIV Antibodies that Mimic CD4 Binding 
 
Introduction 
In our initial studies(Scheid et al., 2008; Scheid et al., 2009a), we established a new and 
highly efficient method to portrait the B cell response against the gp140 envelope protein 
in patients with broadly neutralizing serum activity. One of the surprising findings in our 
experiments was that the gp140 specific B cell repertoire displays high levels of somatic 
hypermutation. Also, VRC01, an antibody with unusually broad and potent activity 
directed to the CD4 binding site (CD4bs) shows high levels of somatic mutations that are 
essential for its activity(Wu et al., 2010; Zhou et al., 2010). As mentioned above, this 
high frequency of mutations is a potential impediment to antibody identification because 
the mutated sequences may no longer be complementary to the primers used for 
immunoglobulin gene amplification(Wardemann et al., 2003). 
To avert this potential difficulty, we developed a new primer set specifically designed to 
address this problem (the 5’ primer is set further upstream to avoid the mutated region) 
(Fig. 10 and Table 4). 
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The envelope trimer of HIV is believed to be a flexible structure(Kwon et al., 2012; 
Poignard et al., 2001). Comparison of the gp120 binding of antibodies b12(Chen et al., 
2009; Dey et al., 2007; Dey et al., 2009b) and VRC01 (Wu et al., 2010; Zhou et al., 
2010)with non neutralizing antibodies directed to the CD4 binding site have suggested 
that binding to gp120 in the CD4 bound conformation correlates with neutralizing 
activity. To systematically study the B cell response to gp120 stabilized in the CD4 
bound conformation we included such a core protein (2CC-core(Dey et al., 2009b)) in 
our staining experiments. In contrast to the resurfaced protein used to clone VRC01(Wu 
et al., 2010; Zhou et al., 2010), which was designed to focus on antibodies to the CD4bs, 
the 2CC-core should capture additional antibodies including those specific to the CD4-
induced co-receptor binding site (CD4i)(Chen et al., 2005; Dey et al., 2009b). 
 
 
 
 
 
 
 
 
 
 
 61 
 
Primers for the identification of highly mutated antibodies 
The new amplification strategy was tested by sorting single B cells from a patient with 
high titers of broadly neutralizing antibodies (Pt 8) that bind to 2CC-core lacking the V1-
3 loops (2CC-core(Chen et al., 2005; Dey et al., 2009b), Fig. 10b).  
In side-by-side comparisons, the new primer set increased recovery of IgH chains when 
compared to the original primer set (Fig. 11)(Wardemann et al., 2003). As expected, the 
antibodies obtained with the new primer set were more mutated (Fig.11 a and c) (average 
35.7 vs. 19.8 p=0.0013 and maximum 85 vs. 50 for IgH) and included clones not found 
with the original primer set (Fig. 11, a and b).  
Moreover, the new primers also recovered VRC01-related antibodies from cDNA 
samples isolated from single cells that had been sorted with the original YU2-gp140 
trimer probe(Scheid et al., 2009b; Yang et al., 2000)(Fig. 12a and b). We conclude, that 
VRC01-like antibodies are captured by the YU2-gp140 trimer(Yang et al., 2000), and 
that primers that are specifically designed to clone highly mutated antibodies capture a 
larger fraction of HIV antibodies from the memory B cells of patients with high titers of 
broadly neutralizing antibodies. 
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Figure 10; Highly mutated antibodies captured with new primers. a, Amplification strategy of 
the original (above(Wardemann et al., 2003)) and new (below(Table 4)) primer sets. Red boxes 
indicate the location of the first primer pair on the heavy chain immunoglobulin gene, green boxes 
the location of the second primer pair in the nested PCR approach. Amplification with the new 
primer set follows a semi-nested approach with the same forward primers in the first and second 
PCR. b, Representative flow cytometry plots show sorting strategy on peripheral blood mononuclear 
cells from Pt 8 stained with anti-CD20, anti-IgG and biotinylated 2CC-core. 
 
 
 
 
 
 63 
Table 4; Primers for amplification of highly mutated 
Immunoglobulin V heavy chain genes. Forward priming sites are 
located in the leader region of the respective VH genes and allow 
amplification of highly mutated VH genes in a semi-nested protocol 
with 2 reverse priming sites located in the IgG constant region. 
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Figure 11; Recovery of highly mutated immunoglobulin heavy chains with specific primers. a, Side 
by side comparison of new and original(Wardemann et al., 2003) primer set on 2CC-core sorted single 
cells from Pt 8. Each row represents one amplified heavy chain sequence and rows with the same color 
identify clonally related B cells. Red boxes and (x) in the last two columns indicate successful 
amplification of IgVH genes either with the new primers (Table 4), original primers(Wardemann et al., 
2003), or both. b, Sequences from a summarized as pie chart. Clonal families are shown by differently 
expanded pie slices. The two highly mutated clones that were not amplified with the original primer set 
are shown in striped pie slices. c, IgVH mutations from the same experiment captured by original and 
new primer sets. Each dot represents one IgVH sequence. 
 
 
 
 
 65 
 
Figure 12; Ig V heavy (a) and light chain (b) sequences of new VRC01 clonal members. Framework 
(FR) and CDR regions are indicated. Red shading shows amino acid differences from VRC01. Contact 
residues between VRC01 and gp120 are shown above as closed circles for main and side chain interactions, 
open circles main chain only, and stars side chains only(Zhou et al., 2010). 
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Anti-2CC-core memory antibodies from four donors 
Four unrelated HIV infected individuals, showing high titers of broadly neutralizing 
antibodies were examined using the 2CC-core(Scheid et al., 2011b). Two of these 
individuals, Pt1 and Pt3, had been studied previously, but their cloned antibodies could 
not account for their serologic activity(Scheid et al., 2009a). 576 antibodies from single 
sorted B cells representing 200 different founder B cell clones that were diversified by 
mutation in germinal centers were obtained from a starting population of 1.5X105 IgG+ 
memory B cells (Fig. 13 a and Table 5).  
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Table 5; IgH and IgL chain gene sequence, antibody reactivity, neutralization assay results for 
cloned antibodies. ND indicates not determined. Letters on the right side of the table indicate close clonal 
relatives shown below. Previously published antibodies(Scheid et al., 2009a) are indicated with a red star.  
a-d, Antibodies from 2CC-core reactive IgG B cells from patients 1, 3, 8 and 12. The number of clone 
members with 95% IgH and IgL chain gene sequence homology is indicated and clonal relatives with 
various degrees of somatic mutations are shown in the same color. e, f, Antibodies from gp140 reactive IgG 
B cells from patients 3 and 1. Each clone is represented once with the number of relatives indicated. 
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Figure 13; 2CC-core captures CD4bs antibodies. (a and b) Top line indicates bait used for sorting, 
and below the patient number. The number in the centre of the pies denotes the number of antibodies; 
slices are unique clones and proportional to clone size. Membership of an antibody in a B cell clone is 
determined by sequence analysis, in particular CDR3s and shared V and J genes of paired heavy and 
light chain genes (Table 5). a, Pie charts show a summary of detected B cell clones irrespective of their 
binding epitopes. () Indicate clones found in both YU2-gp140 and 2CC-core sorted cells. b, Pie 
charts show the distribution of antibodies binding to CD4bs, CD4i, CD4ind. (equally affected by 
D368R and I420R), and core (not affected by either D368R or I420R). Dashed lines indicate 
antibodies that were cloned but could not be produced. c, Representative ELISAs on YU2-gp120, 
mutants and 2CC-core. 
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Epitopes and polyreactivity of anti-2CC-core memory antibodies 
Representative members of each expanded founder B cell clone were tested for binding 
to gp120 and were all positive (Fig. 13b and c and Table 5). The site of antibody binding 
on the envelope spike was mapped using mutant proteins that interfere with either the 
CD4bs [gp120(D368R)] (Olshevsky et al., 1990; Pantophlet et al., 2003; Thali et al., 
1991), or the CD4i site [gp120(I420R)](Thali et al., 1993). NIH45-46, which is a VRC01 
variant, and antibodies 3BNC60, 8ANC131, and 12A12 (antibodies selected on the basis 
of neutralizing activity, see below) (Fig. 13c and Table 5) showed binding patterns 
similar to VRC01. Others, including 1B2530, and 8ANC195 could not be classified 
precisely based solely on ELISA. 
As expected from earlier studies on HIV envelope-specific antibodies(Mouquet et al., 
2010), 65% of the antibodies isolated using the 2CC-core were polyreactive (Fig. 14) 
compared to 22.7% polyreactivity in healthy control memory B cells(Tiller et al., 2007) 
and 17.3% in gp140 negative B cells from HIV positive controls(Mouquet et al., 2010). 
Somatic hypermutation was likely required for development of high affinity antigen 
binding and polyreactivity because reversion of 4 representative antibodies to the 
corresponding germline led to complete loss of binding to YU2-gp140(Yang et al., 2000) 
(Fig. 14b and Fig. 15a to c).  
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Figure 14; Polyreactivity of anti-HIV 
antibodies. a, ELISAs measuring the 
reactivity of anti-HIV antibodies against 
double-stranded DNA (dsDNA), single-
stranded DNA (ssDNA), insulin and 
lipopolysaccharide (LPS) were performed 
and evaluated as described(Mouquet et al., 
2010; Wardemann et al., 2003). Dotted 
lines represent the positive control antibody 
ed38(Wardemann et al., 2003). Horizontal 
lines show cut-off OD405 nm for positive 
reactivity. Green and red lines show the 
negative (mGO53) and low positive 
(eiJB40) control antibodies, 
respectively(Wardemann et al., 2003). b, 
Table summarizes the reactivity against 
dsDNA, ssDNA, insulin and LPS (D, S, I 
and L, respectively) of all single tested 
antibodies and their germline counterparts. 
Colors indicate the different levels of 
antibody reactivity for each antigen. Open 
circles identify non polyreactive, closed 
circles  polyreactive antibodies. Purple text 
and "GL" indicates antibodies reverted to 
germline. Red stars indicate antibodies 
from sort with YU2-gp140(Yang et al., 
2000). c, Representative polyreactivity 
ELISAs(Mouquet et al., 2010; Wardemann 
et al., 2003) with positive control antibody 
ed38(Wardemann et al., 2003) shown in 
black dotted lines and low positive (eiJB40) 
control shown in red dotted lines. 
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Figure 15; Binding and neutralization of mutated and germline antibodies. a, Binding of 
selected antibodies (Table 5) and their germline versions against YU2-gp140 as measured by 
ELISA. Dotted black line shows b12(Burton et al., 1991), solid blue line 3BNC60, green 
8ANC192, orange 12A12 and red 1NC9 (Table 5). b, Antibody binding to YU2-gp140 
measured by surface plasmon resonance (SPR). The SPR sensorgrams for antibody binding of 
the selected antibodies and their germline counterparts are shown. The antibodies were tested 
at concentrations ranging from 44.8 nM (light blue curve) to 700 nM (dark blue curve). RU, 
response units. c, Bar graphs show the binding of the selected antibodies (Table 5) and their 
germline versions to ssDNA, dsDNA, Insulin and LPS (from dark to light blue) (OD405nm) 
at an antibody concentration of 1µg/ml. d, IC50 neutralization titers of the selected antibodies 
and germline versions against a basic virus panel (Table 6). Colors indicate concentration at 
IC50: red ≤ 0.1μg/ml; orange 0.1-1 μg/ml; yellow 1-10μg/ml; green ≥10μg/ml; white not 
neutralized at any concentration tested. 
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HIV neutralizing activity 
HIV neutralizing activity was measured in vitro using an initial panel of 8 viruses 
including 3 tier 1 Clade A, B and C, and 5 tier 2 Clade B envelope (Env) pseudovirus 
variants(Li et al., 2005; Seaman et al., 2010). The neutralizing activity of the antibodies 
was compared to VRC01 and purified serum IgG from the donors (Fig. 16a)(Scheid et 
al., 2011b). A selection of 11 representative antibodies showing high levels of 
neutralizing activity were further tested on a panel of 15 additional tier 2 Env pseudovirus 
variants (Fig. 16b), including 5 viruses that are resistant to VRC01 (Fig. 16 b). 88% of all 
of the antibodies tested showed some neutralizing activity and 6 clones (RU01, 08, 10, 
12, 16 and NIH45-46) contained antibodies that were highly potent and broad (Fig. 16). 
These clones were also the most abundant among those captured by 2CC-core in each of 
the four patients studied (Fig. 13 A and Table 5). Five antibodies representing four 
different broadly neutralizing founder B cell clones [Clone RU01 (3BNC117, 3BNC55) 
Clone RU16 (12A12) Clone RU12 (8ANC195) and NIH45-46], were tested against an 
expanded panel of 118 tier 2 viral isolates from all known clades including 32 transmitted 
founder viruses (Fig. 16c and Table 7) (VRC01 had previously been tested on 82 of 
these)(Wu et al., 2010). The most impressive of the new antibodies, 3BNC117 belonging 
to a clone with 85 members (RU01), showed an average IC80 on a combined group of 95 
tier 2 viruses of 1.4μg/ml (Table 7b).  
When compared to the previously published VRC01 neutralization data only 17 of the 
viruses tested were more sensitive to VRC01 than 3BNC117 and 3BNC117 showed 
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greater breadth (Fig. 16b, c and Table 7) (Wu et al., 2010). NIH45-46 a new variant of 
VRC01 is more potent than VRC01 on 62 of the viruses tested but still less potent than 
3BNC117 (Fig. 16, B and C and Table 7)(Wu et al., 2010). Together the new antibodies 
neutralize 96% of the 118 viruses tested (Table 7). Finally, the best antibodies were 
highly hypermutated, and this was essential for their breadth and potency (Fig. 15 and 
Table 7). 
 
Figure 16; Antibodies captured by 2CC-
core have broad and potent HIV 
neutralizing activity. a, HIV neutralizing 
activity assayed on a limited panel of viruses. 
Top line indicates the donor number. 
Antibody clones are grouped, and individual 
clonal relatives are represented by a column 
grouped as in Table 6. Each row represents 
one virus as indicated on the left. Colors 
indicate concentration at IC50: red, ≤0.1 
mg/ml; orange, 0.1-1 mg/ml; yellow, 1-10 
mg/ml; green, ≥10 mg/ml; white not 
neutralized at any concentration tested. () 
indicates the representatives selected for the 
extended virus panel. b, HIV neutralizing 
activity assayed on an extended panel of 
viruses. c, Neutralization summary graph 
comparing the published IC50 values of 
VRC01(Zhou et al., 2010) with NIH45-46 
and 3BNC117 (Tables 6 and 7). Each color 
represents a different HIV Clade (black 
corresponds to CRF01AE, blue to Clade B, 
green to Clade G, pink to clade D, grey to 
Clade CD, emerald to Clade C, brown to 
Clade ACD, magenta to Clade AC, red to 
Clade A and orange to CRF02AG). Length of 
lines and size of circles are inversely 
proportional to IC50. The distance between 
the outer and inner circle as well as from the 
inner circle to the center of the spiders each 
span two logs in IC50 concentration. 
 76 
 
Table 6; Neutralizing activity of 2CC-core binding antibodies against a basic virus panel of 3 Tier 1 (Clades A, B, C) and 5 Tier 2 
(Clade B) viruses. Each column represents one antibody and antibody clones are grouped for each source patient (Table 5). Tier 1 viruses 
are: MW965.26 (Clade C), BaL.26 (Clade B), DJ263.8 (Clade A); Tier 2 (Clade B) viruses are: 6535.3, RHPA4259.7, TRO.11, PVO.4, 
YU2.DG. Colors indicate concentration at IC50 (a-d) and IC80 (e-h): for monoclonal antibodies: red ≤ 0.1μg/ml; orange 0.1-1 μg/ml; 
yellow 1-10μg/ml; green ≥10μg/ml; white not neutralized at any concentration tested. Previously published data from antibodies 
B12(Burton et al., 1991; Scheid et al., 2009a; Zhou et al., 2010) and VRC01(Zhou et al., 2010) is added as control; for serum IgG: orange 
10-100μg/ml; yellow >100μg/ml; white not neutralized at any concentration tested 
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Table 7; Neutralizing activity of selected antibodies against an extended Tier 2 virus panel.  
Colors indicate concentration at IC50 a and IC80 b: red ≤ 0.1μg/ml; orange 0.1-1 μg/ml; yellow 1-10μg/ml; 
green ≥10μg/ml; white not neutralized at any concentration tested. Previously  
published neutralization data from antibody VRC01 is added as control. c, Summary table of neutralizing 
activity shows the % of viruses from the indicated clades neutralized <50 and <1mg/ml respectively.  The 
Average expresses the arithmetic mean concentrations needed to neutralize the viruses that are sensitive to 
the respective antibodies. 
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Anti-2CC-core antibodies in the bone marrow plasma cell compartment 
Our cloning strategy captures antibodies produced by antigen binding memory B cells in 
the blood, but circulating antibodies are not produced by these cells, and originate instead 
from plasma cells in the bone marrow(Dorner and Radbruch, 2007). To determine 
whether the antibodies cloned from memory B cells are also found in the bone marrow 
plasma cell compartment, we purified plasma cells from paired bone marrow samples 
from patients 3 and 8 (Fig. 17) and used PCR to specifically amplify IgVH genes from the 
clones RU01 and RU10 from memory B cells in these individuals (Fig. 16a, Fig. 17a, and 
Table 5). Members of these clones and large numbers of additional variants were readily 
identified in the respective plasma cell samples (Fig. 17b and c). We also verified that 
antibodies from clones RU01, RU08 and RU10 (Fig. 16a and Table 5) are found in serum 
by mass spectrometry (Fig. 18 and Table 8). 
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Figure 17; Clone specific amplification of IgG genes from CD138+ bone marrow plasma cells. a, 
FACS plot showing sorting strategy for bulk sort of CD19+, CD138+ bone marrow plasma cells. (b and c) 
Phylogenetic trees based on predicted amino acid sequences of members of the b, RU01 clone (Pt 3) and 
c, RU10 clone (Pt 8). Antibodies that were also isolated from the peripheral memory B cell compartment 
are shown in red. Clone specific primers were: for RU01 
CTGCAACCGGTGTACATTCTCAAGTGCAACTGGTGC (FWRD), 
CTGCAACCGGTGTACATTCTCAGGTCCATTTGTCACAG (FWRD), 
TGCGAAGTCGACGCTGACGAGACAGTGACCTGC (REV), 
TGCGAAGTCGACGCTGAAGAGACAATAATTTG (REV), 
TGCGAAGTCGACGCTGACGAGACAATAACT (REV) and for RU10: 
CTGCAACCGGTGTACATTTTCAGGGGCACTTGGTG (FWRD), 
TGCGAAGTCGACGCTGAGGTGACGATGACCGTG (REV). 
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Figure 18; Detection of antibodies by mass spectrometry.  
(a and b) Two sample spectra of collision activated dissociation MS/MS recorded on the doubly charged 
peptides HSDYCDFDVWGSGSQVIVSSASTK from 3BNC153HC a, (Table 5) and 
DGLGEVAPAYLYGIDAWGQGTTVIVTSASTK from 8ANC134HC b, (Table 5). Observed b-type 
fragment ions (containing the N-terminus) and y-type fragment ions (containing the C-terminus) are labeled 
in the spectrum. Loss of water from fragment ions is indicated by *. Ions corresponding to the loss of water 
from the parent ion are labeled in the spectrum.  The complete data set for the peptides detected is shown in 
Table 8. c, Amino acid sequences of 3BNC60, 1B2530 and 8ANC134 heavy chains with peptides found by 
Mass Spec in red. Red dots indicate differences from respective germline sequences. 
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Table 8; Antibody sequences from one expanded  neutralizing clone in each (a) Pt1, (b) Pt3 and (c) 
Pt8. Clone labeling as in Table 5. Peptides identified by mass spectrometry are indicated in color. The  
variants marked with an asterisk are uniquely defined by one or more mass spectrometrically observed 
peptides (shown in yellow). The remaining mass spectrometrically observed peptides map non-uniquely to 
multiple variants as shown in red. Underlined amino acids indicate non-tryptic cleavage sites in the variants 
shown. The cleavages are presumed to occur through chymotryptic cleavage or additional mutations (not 
observed among the cloned variants) that place a lysine or arginine residue at these sites. 
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Affinity of anti-2CC-core antibodies 
To determine whether antibody affinity to gp120 is related to neutralizing activity, we 
compared the binding of the highly active antibodies, selected clonal relatives and 
germline reverted progenitors using Surface Plasmon Resonance (SPR) (Figs. 15, 19a, b 
and 20; Table 9). The top neutralizing antibodies showed affinities (KA) ranging from 
≅107-1012 (M-1) to YU2-gp140 trimers(Yang et al., 2000) and ≅107-1011 (M-1) to the 2CC-
core(Dey et al., 2009b) (Fig. 16a, b and Table 9(Scheid et al., 2011b)). Consistent with 
their decreased neutralizing potency and breadth, 3BNC66, 3BNC156 and 3BNC55 
displayed lower affinities to the YU2-gp140 trimer than 3BNC117, but surprisingly, the 
affinities of these antibodies to 2CC-core did not correlate with their neutralizing activity 
(Figs. 16, 20 and Tables 6 and 8). Finally, we were unable to detect binding by any of the 
germline reverted antibodies tested (Figs. 15b, 19b, and Table 9). We conclude that the 
antibodies captured by the 2CC-core tend to show higher affinity to the YU2- gp140 
trimer than to the 2CC-core. 
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Figure 19; Binding 
properties of antibodies. a, 
Representative SPR 
sensorgrams for binding to 
YU2-gp140 and 2CC-core 
by 12A12, 12A21 (Table 5) 
and 12A-germline (GL) 
reverted antibodies. b, 
Graph shows KA for 
representative antibodies 
(Table 5). c, Graph shows 
mean fluorescence intensity 
of CD4i antibody 3-
67(Scheid et al., 2009a) 
binding to Bal expressing 
293T cells after incubation 
with the indicated 
antibodies. Table indicates 
whether or not an antibody 
induces CD4i site 
accessibility. 
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Figure 20; Affinity of RU01 clone members (Pt 3). a, Antibody binding to YU2-gp140(Yang et al., 
2000)  and 2CC-core(Dey et al., 2009b)  measured by surface plasmon resonance (SPR). The SPR 
sensograms for antibody binding of the selected 3BNC-antibodies are shown over time. b, Bar graphs show 
the binding affinity (KA) for gp140 and 2CC-core antigens for the selected IgG antibodies shown in a, RU, 
response units. 
 
Table 9; Affinity of IgG antibodies to YU2-gp140 and 2CC-core ligands measured  
by surface plasmon resonance. 
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CD4 agonistic function of 2CC-core antibodies 
WhenVRC01 binds to the HIV spike it produces large conformational changes that 
mimic CD4 binding and expose the CD4i site(Wu et al., 2010). By contrast, the broadly 
neutralizing antibody b12(Burton et al., 1991) and many other known CD4bs antibodies 
do not(Moore and Sodroski, 1996). To determine whether the ability to mimic CD4 is a 
shared feature of the most potent antibodies (Tables 6 and 7), we expressed two different 
HIV spikes(Pietzsch et al., 2010a) on the surface of HEK 293T cells and measured CD4i 
antibody binding in the presence or absence of CD4 or CD4bs antibodies (Fig. 19c). With 
one exception, all of the antibodies tested resemble CD4 and VRC01 in that they 
facilitate CD4i-antibody binding to one or both viral spikes (Figs. 19c and 21). The only 
antibody tested that did not share this characteristic, 8ANC195, was not a traditional 
CD4bs antibody in that it was equally sensitive to the D368R and I420R mutations (Fig. 
13c and Table 5), and it differed from the others in its neutralization pattern (Fig. 16a and 
b; and Tables 6 and 7). 
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Figure 21; Effect of sCD4 or monoclonal antibodies on binding of a CD4i antibody (3-67(Scheid et al., 
2009a)) to 293T cells expressing two different HIV spikes. To characterize the newly identified 
antibodies we measured changes in binding of the CD4i antibody (3-67(Scheid et al., 2009a)) in the 
presence of soluble CD4 or the selected antibodies (Table 5). sCD4 or antibodies of interest were added to 
(a) BAL gp160Δc or (b) YU2 gp160Δc expressing 293T cells at different concentrations (1:4 dilutions, 
starting with 40μg/ml), followed by incubation with an Alexa647-labeled CD4-induced-site antibody (3-67, 
red line). In addition, surface expression of gp160Δc was tested with Alexa-647-labeled 2G12(Trkola et al., 
1996) or PG16(Walker et al., 2009)(grey lines). As a reference the binding curves of 3-67(Scheid et al., 
2009a) in the presence of the CD4bs antibody VRC01(Wu et al., 2010)(blue line) and the non-HIV reactive 
antibody mGO (black line(Wardemann et al., 2003)) is illustrated in all graphs. 
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Sequence Conservation of CD4bs Antibodies 
To determine whether highly active CD4bs antibodies share common sequence features, 
we aligned the 10 best antibodies: 2 variants each from independently derived antibody 
clones arising in each of the 4 patients studied and from NIH45 (Fig. 12, Fig. 22a and 
b)(Wu et al., 2010). Comparison of the IgVH regions revealed a conserved consensus 
sequence covering 68 IgVH residues (Fig. 22A). Interestingly, the IgVH consensus 
contains 7 VRC01-gp120 contact residues, including Arg 71VRC01, which mimics the key 
interaction of Arg59CD4 and Asp368gp120 (Fig. 22a) (Kwong et al., 1998; Zhou et al., 
2010). All 10 antibodies arise from only two closely related germline IgVH genes that 
conserve 6 contact residues (Figs. 22a, 23a, and Table 5). The codons of the consensus 
residues are highly somatically mutated in the 10 selected antibodies, however, the ratio 
of replacement to silent mutations in the consensus residues ranges from 0.7 to 1.7, 
whereas it is 3.5-22 in the non-consensus residues indicating that conservation of the 
consensus is strongly selected (Fig. 24 and Table 10). The light chain of VRC01 makes 
fewer contacts with gp120(Zhou et al., 2010). Consistent with its more limited role, 
comparison of the light chain sequences of the same antibodies uncovers a less extensive 
consensus covering 53 IgVL residues, which includes 3 VRC01-gp120 contact residues 
(Figs. 12b and 22b). Finally, like the heavy chains, the light chains arise from a limited 
set of germline genes: 2 are derived from IgK1D-33, 2 from IgK3-11, and one from 
IgL1-47 (Figs. 22b, 23b, and Table 5)(Zhou et al., 2010). Interestingly, antibody 
8ANC195, which differed from the others in several important respects (Figs. 13c, 16b, 
and 19c, 21 and Tables 6 and 7) did not entirely conform to the consensus and did not 
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arise from related heavy or light chains (Fig. 22a and b and Table 5). Thus, there is 
significant sequence convergence among highly active agonistic CD4bs antibodies 
(HAADs). 
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Figure 22; Sequence and structural conservation of HAADs. a, Amino acid alignment of 10 selected 
HAADs (Table 5), their germline genes, and 8ANC195. Residues are numbered according to the 3BNC60 
structure. Framework (FR) and CDR regions are indicated. Red shading shows amino acid identity, yellow 
shows biochemical similarity. 70% similarity between the 10 selected HAADs defined the consensus. The 
consensus sequence is shown above, dashes in this sequence indicate non-conserved residues. Contact 
residues between VRC01 and gp120 are shown above the consensus as closed circles for main and side 
chain interactions, open circles main chain only, and stars side chains only(Zhou et al., 2010). (b) As in (a) 
for light chains. (c, d, and e) Crystal structure of 3BNC60 Fab. c, Superimposed Cα traces of the two Fab 
molecules in the 3BNC60 asymmetric unit are shown in green and red. Semi-transparent surfaces are used 
to outline the heavy (cyan) and light (grey) chains. d, Superimposition of the 3BNC60 VH (red Cα trace) 
and VRC01 VH (cyan Cα trace) shown with a ribbon representation of the CD4 binding loop. The salt 
bridge between Arg71VRC01 and Asp368gp120 is shown as dashed lines. e, Superimposition of the 3BNC60 
VL (red Cα trace). Hydrogen bonds between VRC01 and gp120 are shown as dashed lines. 
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Figure 22 
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Figure 23; Phylogenetic tree of (a) IgVH and (b) Ig light chain germline sequences. Red shows 
position of germline genes used by highly active agonistic anti-CD4bs antibodies. 
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Figure 24; Somatic hypermutation analysis of selected antibodies for (a) immunoglobulin heavy 
chain gene, (b) light chain kappa and (c) light chain lambda gene sequences. Sequences are aligned 
with their respective germline nucleotide sequences. Somatic mutations are shown in red letters, 
additionally gray boxes designate replacement mutations. Germline amino acid sequences with star 
indicating consensus residues are shown above the nucleotide alignment. 
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Table 10; Replacement/Silent mutation ratios for 
heavy (A) and light chain (B)  
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Structural conservation of HAADs 
To determine whether the structure of the antibodies in different patients is also 
conserved, we solved the crystal structure of the 3BNC60 Fab to 2.65 Å resolution and 
compared it to VRC01 (Fig. 22c, d and e). Superimposition of the VH domains from 
3BNC60 and VRC01 in the VRC01-gp120 co-crystal structure(Zhou et al., 2010) yields a 
root mean square deviation (rmsd) of 1.3 Å (calculated for 111 Cα atoms) with major 
differences confined to CDR2 residues 58–65 (3BNC60 numbering). Superimposing the 
structures suggests conservation of the recognition interface with gp120 (Fig. 22d). For 
example, Arg723BNC60 adopts a similar conformation as Arg71VRC01, which mimics an 
important salt bridge normally formed between Arg59CD4 and Asp368gp120 (5, 25). 
Gln653BNC60, which corresponds to Gln64VRC01, is within the residue segment (residues 58–
65) that differs in structure from VRC01. The conformation of this region of 3BNC60, 
which is involved in a lattice contact in the crystals, is likely to change upon binding 
gp120, as it would clash with the CD4-binding loop on gp120. Superimposing the 
3BNC60 and VRC01 VL domains yields a rmsd of 0.9Å (calculated for 95 Cα atoms) 
and shows that some of gp120-contacting residues are structurally conserved (Fig. 22e); 
Tyr913BNC60 and Glu903BNC60 adopt similar conformations as Tyr91VRC01 and Glu96VRC01, 
which engage loop D of gp120 via polar interactions (Fig. 22e). The VH and VL domains 
of the two Fabs show similar interdomain interactions and overall orientation, as 
superimposition of the VH and VL domains of 3BNC60 and VRC01 yields an rmsd of 
1.4 Å (calculated for 206 Cα atoms). Overall, these structural comparisons suggest that 
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3BNC60 binds gp120 with the same architecture as observed for the binding of 
VRC01(Zhou et al., 2010). 
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Discussion 
Our experiments define a class of agonistic CD4bs antibodies, HAADs, that shares IgVH 
and IgVL consensus sequences including 10 of the contact residues between VRC01 and 
the HIV spike (Fig. 22a and b). In five different donors, these antibodies originate from 
only 2 closely related IgVH and 3 IgVL genes (Fig 22a and b). Although we cannot 
exclude the possibility that using the 2CC-core as bait for single cell sorting might 
introduce a selection bias, gp140 sorts performed on two of the donors did not reveal 
additional broadly neutralizing antibodies (Table 5 and 6), suggesting that a significant 
fraction of the CD4 binding site-directed repertoire was captured in our experiments. 
Thus, the repertoire of antibodies that are available to solve the problem of broad and 
potent HIV neutralization by binding to the CD4bs appears to be somewhat restricted. 
Despite this restriction, HAADs account for a significant fraction of the memory B cell, 
and plasma cell compartments, and the circulating IgGs in the patients tested. Therefore 
HAADs are not rare, and once elicited, they contribute to the circulating antibody pool in 
patients that neutralize the virus broadly. However, HAADs are not found in all patients 
with high titers of broad neutralizing activity(Dhillon et al., 2007; Li et al., 2007; Walker 
et al., 2009). Moreover, broad neutralization can be achieved by targeting epitopes other 
than the CD4bs(Buchacher et al., 1994; Muster et al., 1993; Purtscher et al., 1994; Trkola 
et al., 1996; Walker et al., 2011; Walker et al., 2009; Zwick et al., 2001a)  or by 
combinations of antibodies to different epitopes (Scheid et al., 2009a; Zwick et al., 
2001b), or even combination of different CD4bs antibodies (Table 7). 
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The high levels of neutralizing activity displayed by HAADs appears to be correlated 
with binding to a specific surface, which is similar, but not identical, to that contacted by 
CD4(McClure et al., 1987; Zhou et al., 2010). Why a specific type of binding that mimics 
CD4 appears to be required is not known(Wu et al., 2010); however, it has been 
suggested that binding of soluble CD4, or CD4 mimetic compounds, to the HIV envelope 
trimer leads to the formation of a meta-stable intermediate that decays rapidly and loses 
the ability to fuse(Haim et al., 2009). We speculate that HAAD binding mimics soluble 
CD4, and destabilizes the trimer. Irrespective of their mechanism of action, HAADs 
might contribute to viremic control in a subset of HIV infected individuals, and may be 
useful in HIV prevention or possibly even therapy because of the low concentrations 
required for viral neutralization. 
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Chapter 4 
Discussion 
 
Until recently our understanding of broadly neutralizing activity against HIV was very 
limited. We have pioneered a new technique to investigate such responses efficiently and 
with unprecedented resolution. Together with others this has given us the opportunity to 
transform our understanding of HIV neutralization. This chapter will discuss 
improvements of our structural view of neutralization before focusing on other features of 
the neutralizing HIV B cell response.  
Neutralizing Epitopes 
In contrast to previous assumptions broad neutralization targets a diversity of different 
epitopes on the HIV envelope. On gp120 even variable regions such as the loops V1/2 
and V3 are targeted by broad neutralization. The identification of neutralizing epitopes is 
far from complete and extensive analysis of more patients is required. 
CD4 binding site 
The CD4bs is a frequent target of highly potent broadly neutralizing responses. For 
HAADs, there is a striking conservation of the immunological pathway to this activity 
(Falkowska et al., 2012; Lynch et al., 2012; Scheid et al., 2011b; Wu et al., 2010; Wu et 
al., 2011; Zhou et al., 2010). Remarkably, this conservation includes the repertoire of 
germline sequences, which seems to be restricted to 2 heavy chain genes. We speculate, 
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that specifically targeting this germline repertoire might help in vaccine design. This 
could be achieved by selecting antigens with high affinity to the germline version of 
HAADs. 
Not all CD4bs directed broad neutralizers can be classified as HAADs. Several recently 
identified broadly neutralizing CD4bs antibody clones do not act as CD4 agonists on the 
surface trimer and show a different pattern of neutralization in large pseudovirus 
screens(Falkowska et al., 2012; Liao et al., 2013; Scheid et al., 2011b). Not all of these 
have been co-crystallized with gp120 yet and the structural definition of their epitopes 
will provide insight into alternative ways of approaching the CD4bs. However, these 
antibodies share with HAADs a high affinity to gp120 stabilized in the CD4 bound 
conformation.  
Variable loops 1/2 
Single cell analysis of B cells that were selected based on their neutralizing activity rather 
than their binding characteristics(Walker et al., 2009) revealed new broadly neutralizing 
epitopes. Two of these antibodies, PG9 and PG16 are directed to an epitope that includes 
the base of variable loops 1/2. Co-crystals of PG9 with a V1/2 scaffold proves that most 
of the antibody epitope consists of a Man5GlcNAc2 residue at position 160 of gp120 
(strains CAP45 and ZM109), as well as glycan residues 156 (CAP45) or 173 
(ZM109)(McLellan et al., 2011). With its CDR3, antibody PG9 penetrates the glycan 
shield of the envelope at position 160 and grasps the entire glycan up to the protein 
proximal N-acetylglucosamine(McLellan et al., 2011). In addition to these glycan sites 
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PG9 also forms hydrogen bonds as well as electrostatic interactions with strand C of 
V1/V2. Other representatives of this class of antibodies were identified recently 
(PG16(Walker et al., 2009), CH01-04(Bonsignori et al., 2011), PGT141-145(Walker et 
al., 2011)).  These antibodies compete with each other in binding assays. Also, binding as 
well as neutralization of this group of antibodies depends on the N160 residue, 
confirming that they target an overlapping region on the HIV envelope.   
Variable loop 3 
Another group of broadly neutralizing antibodies (PGT127 and PGT128(Walker et al., 
2011)) was also found to mainly interact with glycan residues. These antibodies have a 
primary binding site at the Man 8/9GlcNAc2 of position N332 of the gp120 outer 
domain(Pejchal et al., 2011). The secondary binding site is focused on the core 
pentasaccharide attached to N301 on the V3 loop(Pejchal et al., 2011). The importance of 
these residues was confirmed functionally by decreased binding and neutralization 
sensitivity of point mutants(Pejchal et al., 2011). In addition to the two independent 
glycan binding sites, the antibodies also interact with the C terminal V3 stem, supporting 
a model of heteroligation(Mouquet et al., 2010) within one combined antibody binding 
site. 
Further neutralizing epitopes 
As mentioned above, we and other groups are currently investigating further patients and 
selection methods for single B cell analysis. These attempts will very likely uncover 
further neutralizing epitopes on the envelope surface. Follow up studies on patient 3, 
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from which highly potent CD4bs antibodies were isolated(Scheid et al., 2011b) have 
yielded two different antibodies directed to a new epitope in the vicinity of the V3 loop 
and the CD4i site (Klein et al., 2012a).  Although far not as broad and potent as the 
CD4bs antibodies from this donor, their activity seems to complement the CD4bs 
directed neutralizing activity. In addition to introducing a further new neutralizing 
epitope, this study most importantly emphasizes complementary activity of diverse 
neutralizing antibodies within one patient (Bonsignori et al., 2012; Klein et al., 2012a)). 
Characteristics of the B cell response 
Mutations and Clone Evolution 
Single cell analysis revealed characteristic molecular features of the HIV neutralizing B 
cell repertoire. High levels of somatic hypermutation are required for neutralization, 
because reversion leads to loss of binding and neutralizing activity in broad 
neutralizers(Mouquet et al., 2010; Scheid et al., 2011b; Zhou et al., 2010) (Bonsignori et 
al., 2011; Scheid et al., 2011b; Walker et al., 2011; Walker et al., 2009; Wu et al., 2010). 
This is true even when only non-contact sites in the scaffolding framework regions are 
reverted (Klein et al., 2013).  
At the same time extensive somatic hypermutation carries the risk of a non-functional 
immunoglobulin or introducing AID mediated translocations(Muschen et al., 2000; 
Nussenzweig and Nussenzweig, 2010; Odegard and Schatz, 2006; Pasqualucci et al., 
2001; Shen et al., 1998). In most immune responses somatic hypermutation is limited, 
because there is no selection advantage for an antigen off rate beyond the speed of 
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antibody internalization(10-3-10-4s-1)(Batista and Neuberger, 1998; Foote and Eisen, 
1995).  
It is not clear, why so many somatic mutations are required in HIV infection and if 
similar levels of mutations are achieved in other chronic infections. However, the 
diversity of epitope versions in the course of chronic HIV infection (Wei et al., 2003) 
might play a role. We speculate that broadly neutralizing epitopes such as the CD4bs 
represent functionally conserved regions on the envelope that nevertheless undergo 
constant changes. These changes might lead to recall of B cell clones into germinal 
centers for further rounds of affinity maturation. It is possible that over time these recalls 
lead to neutralization breadth and therefore should be copied in a sequential vaccine 
approach.  
In supportof of this model of "chronic" affinity maturation a recent study has tracked one 
evolving CD4bs B cell clone for over 100 weeks of infection (Liao et al., 2013). Most 
importantly, the authors were able to isolate several intermediate viral envelopes with 
their respective binding antibody intermediates and characterized both structurally. This 
is particularly exciting as combining the recently developed techniques for monoclonal 
antibody investigations with viral isolation in this fashion might be a very valuable tool in 
the near future to portrait numerous "maps to neutralizing serum activity". 
 CDR3 length and polyreactivity 
Long CDR3 regions(Bonsignori et al., 2011; Cardoso et al., 2005; McLellan et al., 2011; 
Ofek et al., 2004; Scheid et al., 2011b; Walker et al., 2011)as well as polyreactivity 
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(Haynes et al., 2005; Mouquet et al., 2010; Scheid et al., 2011b)are further common 
features of several broad neutralizers.  
Extended CDR3 regions are generated during V(D)J recombination (Tonegawa, 
1983)and nucleotide addition early in B cell development and to a lesser extent during  
somatic hypermutation(Scheid et al., 2011b; Wilson et al., 1998).  
Increased CDR3 length is associated with polyreactivity(Ichiyoshi and Casali, 1994) and 
extensive single cell analysis of B cell compartments has shown that both features are 
selected against during B cell maturation(Wardemann et al., 2003). This selection is 
achieved by developmental checkpoints that reduce the risk of autoimmunity(Yurasov et 
al., 2005). Nevertheless, long CDR3 regions are functionally important elements of 
several broad neutralizers. This was shown in particular for broadly neutralizing 
gp41(Cardoso et al., 2005; Ofek et al., 2004) and variable loop (McLellan et al., 2011; 
Pejchal et al., 2011)directed antibodies. In addition, 45-46, one of the most broad and 
potent CD4bs antibodies is a clonal member of VRC01 and acquired its additional 
activity through a 4 residue insertion in the CDR3 region. The insertion leads to increased 
contact with the gp120 inner domain. Overall, a large fraction of broad neutralizers 
require long CDR3 regions for their activity and vaccine efforts might have to 
specifically target this fraction of the B cell compartment. 
Similarly, polyreactivity is selected against throughout B cell development(Scheid et al., 
2011a; Tiller et al., 2007; Wardemann et al., 2003). However, a large fraction of broadly 
neutralizing antibodies are polyreactive, which might be an efficient means to address 
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low antigen density on the viral surface of HIV because it allows simultaneous binding of 
both Fab arms(Mouquet et al., 2010). In "heteroligation", one arm binds specifically with 
high affinity to the cognate antigen, whereas the second arm binds unspecifically with a 
polyreactive interaction, thereby increasing the overall binding avidity(Mouquet et al., 
2010). It is not clear, which role heteroligation plays in vivo. However, vaccine design 
might attempt to mimic low density interactions in order to elicit polyreactive antibodies 
with higher avidity. 
Broadly neutralizing HIV antibodies can protect against infection and are produced 
frequently in immune responses against this virus. Our single cell analysis has provided 
valuable and long-sought insight into structural and developmental features of broad HIV 
neutralization. Using the methods and antibodies described in this work, we will 
hopefully be able to address how to phenocopy such a response with a vaccine. Of note, 
never before has a vaccine been designed "reversely" by starting with neutralizing 
antibody epitopes and generating footprints of these targets.  One of the main challenges 
in this approach will be the differentiation between binding and neutralizing antibodies. 
Neutralization is not selected for in an immune response. Therefore, it will be necessary 
to find reagents that selectively bind to and elicit neutralizing antibodies.  
Another challenge will be the generation of neutralization breadth. Antigen diversity and 
numerous rounds of somatic hypermutation might be involved in the generation of 
breadth(Liao et al., 2013). In support of this idea, recent T cell based vaccine approaches 
have successfully incorporated viral diversity(Barouch et al., 2010; Santra et al., 2010).  
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Finally, in addition to providing new possible vaccine targets and maps to develop 
broadly neutralizing serum activity, the growing number of broadly neutralizing 
antibodies might provide us with new tools in HIV antibody therapy.  
As mentioned above, early studies using the antibodies 2F5, 4E10 and 2G12 had met 
with limited success. Recent experiments in humanized mouse models however suggest 
that a combination of several highly potent broadly neutralizing antibodies is able to 
rapidly reduce and durably control viral loads at undetectable levels without antiretroviral 
treatment(Klein et al., 2012b). The prospect of transferring these findings to different 
clinical settings is an additional exciting door that the investigation of broadly 
neutralizing B cell responses has opened to us.  
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Chapter 5 
Materials and Methods 
 
Samples. Human samples were collected after signed informed consent in accordance 
with Institutional Review Board (IRB)-reviewed protocols by all participating 
institutions. Patient 1 was selected from a cohort of long term non progressors followed 
at the Aaron Diamond Aids Research Center, New York. Patients 2, 3, 5 and 8 were 
selected from a group of elite controllers that were followed at the Ragon Institute in 
Boston. Patients 1, 2, 3, 5 and 8 were selected based on their broad neutralizing serum 
activity against a standard panel of HIV isolates(Li et al., 2005). Patient 12 was selected 
from the Protocol G Cohort of the "International Aids Vaccine Initiative" and patients 4 
and 6 from the cohort of the National Institute of Allergy and Infectious Diseases based 
on broad serum neutralizing activity(Walker et al., 2010).  
Staining, single-cell sorting and antibody cloning. Staining and single cell sorting of 
2CC-core and gp140 specific Ig+ memory B cells was performed as previously 
described(Scheid et al., 2009a; Scheid et al., 2009b; Wardemann et al., 2003). Briefly, 
CD19+ B cells were enriched from peripheral blood mononuclear cells using anti human 
CD19 magnetic MACS beads (Miltenyi Biotec) and subsequently stained with anti 
human CD20 and anti human IgG antibodies (Becton Dickinson) as well as biotinylated 
2CC-core(Dey et al., 2009b) or YU2-gp140 trimer(Yang et al., 2000) followed by 
detection with streptavidin coupled phycoerythrin (PE, Beckton Dickinson). Single cells 
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were sorted on a FACSAria III cell sorter (Becton Dickinson), excluding cell doublets, 
into 96-well PCR plates (Denville) containing 4 μl/well of ice-cold 0.5× phosphate-
buffered saline (PBS) containing 10 mM DTT, 8 U RNAsin® (Promega), 0.4 U 5′-3′ 
Prime RNAse Inhibitor™ (Eppendorf). Plates were sealed with Microseal® ´F` Film 
(BioRad), immediately frozen on dry ice before storage at − 80 °C. 
cDNA synthesis and Ig amplification were performed as previously 
described(Wardemann et al., 2003) and with following modifications: 
Instead of using the original primer sets(Wardemann et al., 2003), first and second 
immunoglobulin specific PCRs were also carried out using the primers described in Table 
4 in a semi-nested approach. In order to amplify immunoglobulin genes that are highly 
somatically mutated the 5’ primers are set further upstream in the leader region to avoid 
the potentially mutated region. These 5' primers (Table 4) are used in both PCR steps 
with different constant region primers in each step (Fig. 10, Table 4). The cloning of 
heavy and light chain PCR products into their respective expression vectors was 
performed as previously described(Wardemann et al., 2003) and 100% identity of cloned 
expression plasmids with the original PCR product confirmed by sequencing before 
expression of the antibodies in HEK 293 cells as previously described(Wardemann et al., 
2003). Clonal relationships are identified by immunoglobulin sequence analysis. 
Antibodies with shared V and J genes for heavy and light chains as well as shared CDR3 
region characteristics and somatic hypermutations are considered members of an 
expanded clone.  
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Deglycosylation of gp120 For deglycosylation 150ug of GP120 was treated with 
PNGase F (New England Biolabs) and O-glycosidase (QA Bio) in 50 mM sodium 
phosphate without denaturing agents and incubated overnight at 37°C to ensue maximal 
deglycosylation. Lectin blots were preformed to verify glycan removal as previously 
described(Kaneko et al., 2006). 
ELISAs. High-binding 96-well ELISA plates (Costar) were coated overnight with 100 
ng/well of purified antigens (gp140, gp120, gp41, gp120core and 2CC-core)(Dey et al., 
2009b; Kwong et al., 1998; Yang et al., 2000) and mutant proteins (gp120 D368R, gp120 
I420R) (Olshevsky et al., 1990; Pantophlet et al., 2003; Thali et al., 1993; Thali et al., 
1991)in PBS. After washing, plates were blocked 2 h with 2% BSA, 1µM EDTA, 0.05% 
Tween-PBS (blocking buffer) and then incubated for 2 hours with IgG antibodies diluted 
at 4 µg/ml and several consecutive 1:4 dilutions in PBS. After washing, the plates were 
developed by incubation for 1 h with goat HRP-conjugated anti-human IgG (Jackson 
ImmunoReseach) (at 0.8 µg/ml in blocking buffer) and by adding 100 µl of HRP 
chromogenic substrate (ABTS solution, Invitrogen). Optical densities were measured at 
405nm (OD405nm) using an ELISA microplate reader (Molecular Devices). Background 
values given by incubation of PBS alone in coated wells were subtracted. IgG Antibodies 
were tested for polyreactivity as previously described (Mouquet et al., 2010) and 
considered polyreactive when they recognized at least two structurally different antigens 
out of the four tested; ssDNA, dsDNA, insulin, and LPS. Threshold values for reactivity 
were determined by using control antibodies mGO53 (negative), eiJB40 (low positive), 
and ED38 (high positive)(Mouquet et al., 2010; Wardemann et al., 2003). 
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Neutralization assays. Neutralization screens were performed as described(Montefiori, 
2005). In brief, neutralization was detected as reduction in luciferase reporter gene 
expression after single round infection in Tzm-bl cells. In order to rule out unspecific 
antiviral activity in antibody samples MuLV (murine leukemia virus) was used as a 
negative control. 
Clone specific identification of bone marrow plasma cells. Bone marrow plasma cells 
were stained with anti human CD138 and anti CD19 antibodies (Becton Dickinson) after 
Ficoll purification of mononuclear cells from bone marrow aspirates using Ficoll-Paque 
(GE Healthcare).  CD138+ CD19+ human plasma cells were bulk sorted on a 
FACSAriaIII cell sorter (Becton Dickinson) and RNA isolation performed on 100,000 
cells using Trizol LS reagent (Invitrogen) according to the manufacturers instructions. 
RNA was reverse transcribed using Superscript III reverse transcriptase (Invitrogen) 
according to manufacturers instructions. cDNA was then subjected to Immunoglobulin 
specific PCR as previously described(Wardemann et al., 2003) with following 
modifications: 1ml of cDNA was amplified in 2 rounds of nested immunoglobulin heavy 
chain clone specific PCR using first round forward leader and constant region reverse 
primers (Table 4) followed by clone specific forward and reverse primers, designed based 
on sequencing results from single cell analysis. PCR products were gel purified and 
cloned into TOPO TA vectors (Invitrogen) according to the manufacturers instructions. 
Colonies were screened by PCR with clone specific primers and sequenced. 
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Surface plasmon resonance. All experiments were performed with a Biacore T100 
(Biacore, Inc) in HBS-EP+ running buffer (Biacore, Inc) at 25ºC as described 
previously(Mouquet et al., 2010). YU2-gp140 and 2CC-core proteins at 12.5 µg/mL were 
immobilized on CM5 chips (Biacore, Inc.) by amine coupling at pH 4.5 resulting in an 
immobilization level of 100 RUs. For kinetic measurements on the gp140- and 2CC-core-
derivatized chips, IgGs were injected through flow cells at 700 nM and 4 successive 1:2-
dilutions in HBS-EP+ running buffer (Biacore, Inc.) at flow rates of 40 μL/min with 3 
min association and 5 min dissociation. The sensor surface was regenerated between each 
experiment with a 30 second injection of 10 mM glycine-HCl pH 2.5 at a flow rate of 50 
μL/min. Off rate (kd (s-1)), on rate (ka (M−1 s−1) and binding constants (KD (M) or KA (M−1) 
were calculated after subtraction of backgrounds (binding to control flow cells and signal 
of the HBS-EP+ running buffer) using Biacore T100 Evaluation software using the 
kinetic analysis and the 1:1 binding model.  
CD4i site induction. 293T cells were transfected with gp160BALΔc or gp160YU.2Δc in a 
pMX-IRES-GFP construct(Pietzsch et al., 2010a) using FugeneTM6 (Roche) at a 1:2 
plasmid/Fugene ratio. After 48 hours 293T cells were washed with PBS, detached with 
trypsin-free cell dissociation buffer (Gibco) and resuspended at a concentration of 107 
cells/ml in FACS buffer (PBS, 2 % fetal bovine serum (FBS), 2 mM EDTA).  sCD4 
(Progenics Pharmaceuticals, Inc.) and monoclonal antibodies were added to gp160-
expressing 293T cells in a 1:4 dilution series starting with a concentration of 40 µg/ml. 
mGO53(Mouquet et al., 2010; Wardemann et al., 2003)is a non-polyreactive negative 
control antibody that does not bind to gp160Δc . After incubation for 15 min on ice cells 
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were stained for 25 min on ice with an Alexa647-labeled CD4-induced site antibody (3-
67;(Scheid et al., 2009a)) or an Alexa647-labeled control antibody (i.e. PG16(Walker et 
al., 2009) or 2G12(Trkola et al., 1996) for gp160YU.2 and 2G12(Trkola et al., 1996) for 
gp160BAL). Antibody labeling was performed by using Alexa Fluor® 647 Microscale 
Protein Labeling Kit (Invitrogen). Cells were analyzed on an LSRFortessa cell analyzer 
(BD Bioscience).   
Crystallization. The 3BNC60 IgG was expressed by transient expression in HEK293-6E 
cells and the Fab fragment was prepared by papain cleavage as described(Diskin et al., 
2010). Crystallization screens were conducted at 20°C by vapor diffusion in nL sitting 
drops using a Mosquito™ (TTP LabTech) crystallization robot on MRC crystallization 
plates (Jena Bioscience). We combined 3BNC60 Fab at a concentration of 9.5 mg/ml 
with reservoir solution in a 1:1 ratio to create 400 nL drops. Initial crystallization hits 
were obtained using the PEGRx HT™ (Hampton Research) crystallization screen and 
further optimized manually. Crystals suitable for data collection grew after several weeks 
in 11.7% polyethylene glycol 20,000, 0.1 M sodium acetate pH 5.0, 100 mM 
potassium/sodium tartrate, 20 mM lithium sulfate, 10 mM N-Cyclohexyl-2-
aminoethanesulfonic acid (CHES) pH 9.5 in the monoclinic space group P21 with two 
Fabs in the asymmetric unit. Crystals were soaked in reservoir solution supplemented 
with 15% glycerol for 2 hours before immersing in reservoir solution supplemented with 
30% glycerol and flash cooling in liquid nitrogen. Diffraction data were collected at the 
Stanford Synchrotron Radiation Lightsource (SSRL) beam-line 12-2 at 100 K using a 
Pilatus 6M detector. Data were indexed, integrated, and scaled using XDS(Kabsch, 
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2010). Molecular replacement was conducted using Phaser(McCoy et al., 2007) with the 
VH and CH1 domains from the anti-tumor antibody CTM01 (PDB code 1AD9) and with 
the VL and CL domains of the gp120 b13 antibody (PDB code 3IDX) as search models. 
Model building and refinement to 2.65 Å resolution was done iteratively using 
Phenix(Adams et al., 2010)and Coot(Emsley et al., 2010). The structure was refined 
using a maximum-likelihood target function and non-crystallographic symmetry 
restraints. The final model (Rwork = 20.7%; Rfree = 25.7%) includes 6478 protein atoms, 
146 water molecules and 28 sugar atoms. 91.9%, 7.6% and 0.5% of the residues were in 
the favored, allowed, and disallowed regions, respectively, of the Ramachandran plot. 
Structural analyses and visualization were done using PyMol (The PyMOL Molecular 
Graphics System, Version 1.3, Schrödinger, LLC). The 3BNC60 structure consists of 
residues 3–205 for the light chain (including the first N-acetylglucosamine within an N-
linked carbohydrate attached to Asn72) and 2–217 for the heavy-chain. Residues at the 
termini residues and residues 133–140 within the CH1 domain are disordered.  
Mass Spectrometry. IgG was purified from serum using Protein G Sepharose (GE 
Healthcare) according to the manufacturers instructions. IgGs were then digested with 
immobilized papain (Pierce) and digested Fab-Fc fragment mixes incubated with 
saturating quantities of biotinylated 2CC-core protein(Dey et al., 2009a). Streptavidin 
coupled Dynabeads (Invitrogen) were added after incubation for 15 minutes at room 
temperature and subjected to 10 rounds of washing with Phosphate Buffered Saline 
(Gibco). Bound Fab fragments were eluted with lithium dodecyl sulfate buffer 
(Invitrogen) at 95˚C and sample purity confirmed with SDS-polyacrylamide gel 
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electrophoresis followed by silver stain or coomassie staining before analysis by mass 
spectrometry. 
Isolated Fab fragments were reduced with dithiothreitol, alkylated using iodoacetamide, 
resolved by 1D gel electrophoresis on a 4-12% NuPAGE Novex Bis-Tris gel 
(Invitrogen), and stained with Coomassie Blue (Thermo Fisher). The Fab fragments were 
excised from the gel, and digested using 200ng of trypsin (Promega). The resulting 
peptides were isolated using reverse phase resin (PORS 20 R2, Applied 
Biosystem)(Krutchinsky et al., 2001) and eluted using an aliquot of 40% acetonitrile in 
0.5% acetic acid and a second aliquot of 80% acetonitrile in 0.5% acetic acid. 
Acetonitrile was removed using a speedvac (Thermo Fisher Scientific) and aliquots of the 
remaining solution pressure loaded onto self-packed PicoFrit® column (New Objective, 
Woburn, MA) with integrated emitter tip (360 µm O.D., 50µm I.D., 10 µm tip), packed 
with 6 cm of reverse-phase C18 material (ReproSil-Pur C18-AQ, 3 µm beads from Dr. 
Maisch GmbH) and interfaced to a Agilent 1200 series HPLC system (Agilent) with 
either a LTQ Orbitrap XL mass spectrometer or a LTQ Orbitrap Velos mass 
spectrometer (Thermo Fisher Scientific) using a home-built micro electrospray source. 
The peptides were eluted into the mass spectrometer with the following gradient: 0 to 5% 
B in 5min, 40% B in 125 min, 60% B in 150 min, 100% B in 165 min (A = 0.1 M acetic 
acid, B = 70% acetonitrile in 0.1 M acetic acid, flow rate 90 nL/min). Both instruments 
were operated in the data dependent mode and for both mass spectrometers the target 
value was set to 5e5 ions and a resolution of 60,000 (at 400 m/z). For analysis on the 
LTQ Orbitrap XL a full scan was followed by 8 MS/MS scans on the 8 most abundant 
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ions from that full scan. The peptides (only charge states >1) were isolated with a 2 Da 
window, target window of 1e4 ions, dissociated via CAD (normalized collision energy = 
35, activation Q = 0.25, activation time 30 msec) and mass analyzed in the LTQ. For 
analysis on the LTQ Orbitrap Velos a full scan was followed by 10 MS/MS scans at 
7,500 resolution on the 10 most abundant ions from the immediate preceding full scan. 
The peptides (only charge state >2) were isolated with a 3 Da window, target window of 
2e5 ions, dissociated via HCD (normalized collision energy = 40, activation time 0.100 
msec) and mass analyzed in the Orbitrap. For either instrument the ions selected for 
MS/MS were set on an exclusion list for 30 seconds. The resulting MS/MS spectra were 
searched against the Human IPI and in-house patient specific IgG database using 
Xtandem!(Craig and Beavis, 2004). Peptides were automatically compared to tryptic 
peptides in the human IPI and our in-house patient specific database. Peptide hits 
corresponding to patient specific IgG were manually confirmed.  
Multiple sequence alignments. All multiple sequence alignments were conducted using 
CLUSTALW2 with default parameters (weight matrix: GONNET for proteins and UIB 
for DNA, gap open= 10, gap extension 0.1). Alignment shadings were generated using 
TeXshade package.  
Alignment consensus. The consensus sequences for multiple alignments were generated 
based on identity and similarity between residues (≥ 70%).  The amino acids were 
grouped based on biochemical similarity as: FYW, ILVM, RK, DE, GA, ST and NQ. 
Phylogenetic Germline Trees. The relationship between sequences was generated using 
the Neighbor-Joining method(Saitou and Nei, 1987). The bootstrap consensus tree 
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inferred from 1,000 replicates(Felsenstein, 1988) was taken to represent the relationship. 
Branches corresponding to partitions reproduced in less than 50% bootstrap replicates are 
collapsed. The percentage of replicate trees in which the associated sequence clustered 
together in the bootstrap test (1,000 replicates) are shown next to the 
branches(Felsenstein, 1988). The tree is drawn to scale, with branch lengths in the same 
units as those of the evolutionary distances used to infer the phylogenetic tree. The 
evolutionary distances were computed using the number of differences method(Kumar et 
al., 1994) and are in the units of the number of amino acid differences per sequence. All 
ambiguous positions were removed for each sequence pair. Evolutionary analyses were 
conducted in MEGA5(Tamura et al., 2007).  
R/S Ratio Calculation. DNA sequences were superposed over the protein alignments for  
replacement/substitution calculation. All gap positions were removed from the analysis.  
The R/S ratio analysis was conducted using Perl scripts. 
Statistical analysis. P value for mutation analysis was calculated using an unpaired two-
tailed students t-test.  
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